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Diabetes is one of the most widely spread diseases in the world nowadays. It can be classified 
into either Type 1, in which there is almost no insulin production, or Type 2, in which there is 
insulin production but it is not enough. In order to treat this disease, the researchers are trying to 
understand the system of glucose–insulin system and to describe its dynamics by using several 
mathematical models. Ordinary differential equations, integral differential equations, partial 
differential equations , delay differential equations, and stochastic models are the five main types 
of most mathematical models. In order to automate insulin delivery to diabetes patients, various 
control techniques are implemented which can be classified as model- independent ( such as 
optimal control )and non-model independent (such as run to run control). The literature shows the 
possibility of automating insulin delivery for diabetes patients. However, no method is fully 
successful due to the complexity of this process, and the number and types of factors involved. 
In the present study we are using a two time-delay model. In terms of control, we are using linear 
matrix inequality tools (LMI) in formulating the control technique which will stabilize the plant 
(patient) and force it to follow the desired pattern or desired model. The new control technique is 
simulated on the selected model, and the results are promising to be implementation in reality. 
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ﺍﻟﻤﺸﻜﻠﺔ ﺑﺸﻜﻞ ﻛﺎﻣﻞ ﻧﻈﺮﺍ ﻟﺘﻌﻘﻴﺪ ﻫﺬﻩ ﺍﻟﻌﻤﻠﻴﺔ ﻭﻋﺪﺩ ﻭﻧﻮﻉ ﺍﻟﻌﻮﺍﻣﻞ ﺍﻟﻤﺮﺗﺒﻄﺔ ﺑﻬﺬﺍ ﺍﻟﻌﻤﻠﻴﺔ. 
 ﻓﻲ ﻫﺬﺍ ﺍﻟﺒﺤﺚ , ﺍﺳﺘﺨﺪﻣﻨﺎ ﻧﻤﻮﺫﺝ ﺭﻳﺎﺿﻲ ﺑﺘﺄﺧﻴﺮﻳﻦ ﺯﻣﻨﻴﻦ ﻟﻮﺻﻒ ﻋﻤﻠﻴﺔ ﺗﻨﻈﻴﻢ ﺍﻟﺠﻠﻮﻛﻮﺯ ﻓﻲ ﺍﻟﺪﻡ .  ﻭﺍﺳﺘﺨﺪﻣﻨﺎ
ﺃﺩﻭﺍﺕ ﺍﻟﻤﺘﺮﺍﺟﺤﺔ ﺍﻟﻤﺼﻔﻮﻓﻴﺔ ﺍﻟﺨﻄﻴﺔ ﻟﺼﻴﺎﻏﺔ ﺗﻘﻨﻴﺔ ﺍﻟﺘﺤﻜﻢ ﺍﻟﺘﻲ ﺗﺠﻌﻞ ﺍﻟﻨﻈﺎﻡ ﻣﺴﺘﻘﺮﺍ  ﻭﺗﺪﻓﻌﻪ ﻟﺘﺘﺒﻊ ﻧﻤﻂ ﻣﻌﻴﻦ ﺫﻭ 
ﺧﻮﺍﺹ ﻣﺨﺘﺎﺭﺓ.  ﻗﻤﻨﺎ ﺑﻌﻤﻞ ﻣﺤﺎﻛﺎﺓ ﻟﻬﺬﺍ ﺍﻟﻨﻈﺎﻡ ﻻﺧﺘﺒﺎﺭ ﺍﻟﺘﺼﻤﻴﻢ ﻭﺃﻇﻬﺮﺕ ﺍﻟﻨﺘﺎﺋﺞ ﺇﻣﻜﺎﻧﻴﺔ ﺗﻄﺒﻴﻖ ﻫﺬﺍ ﺍﻟﺘﺼﻤﻴﻢ ﻓﻲ 
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NOMENCLATURE 
G  =  Blood plasma glucose concentration above basal value. 
I  =   Plasma insulin concentration above basal value. 
Xr  =   Insulin in the remote compartment. 
Gsc  =  Glucose concentration on the subcutaneous layer. 
Dm  = Meal glucose disturbance (mg/dL/min). 
       J   =   Objective function. 
       P  =    Prediction horizon. 
      M   =   Control horizon. 
      K   =   Sample time index. 
      Δu  =  The manipulated input increment. 
       𝑦𝑦�  =  The predicted output. 
𝑥𝑥(𝑡𝑡)  =  State vector. 
𝑢𝑢(𝑡𝑡) =  Control input.  
𝑤𝑤(𝑡𝑡) = Disturbance input.    
𝑧𝑧(𝑡𝑡) = Controlled output.  
𝜏𝜏  =  Constant time delay. 
 
 
 
 
  
  
CHAPTER 1 
 
DIABETES BACKGROUND 
1.1. Introduction 
Diabetes mellitus is a group of metabolic disorders characterized by inability of 
the pancreas to regulate the blood glucose concentration due to defects in insulin 
secretion and/or insulin action, the pancreas either does not release insulin or does not 
properly use insulin to uptake glucose in the plasma [91].  
Insulin, the heart of glucose level control, was discovered in 1921. It has been 
purified and manufactured by recombinant DNA technology. The insulin treatment 
mimics normal physiology in order to prevent the complications of hyper- and 
hypoglycemia. The amount of the injected insulin is typically based on the blood glucose 
level and on the estimated insulin release kinetics from the subcutaneous depot.  
Diabetes mellitus is one of the worst diseases with respect to the size of affected 
population. According to the data published in 2002 by the American Diabetes 
Association [41, 42] 18.2 million people (about 6.3% of the total US population) had type 
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2 diabetes. The direct and indirect cost of the treatment of diabetes was 132 billion 
dollars. The world-wide diabetic population is much higher, especially in underdeveloped 
countries. 
This section gives a medical overview about the diabetes (general terms and 
idiom), and finally the insulin glucose control in the normal patient. 
1.2. Classification of Blood Glucose Levels 
According to The Diabetes Control and Complications Trial (DCCT) Research 
Group [22], blood glucose level has been classified into three main categories: 
Normoglycemia, Hypoglycemia, and Hyperglycemia. 
Normoglycemia is defined as the normal condition with blood glucose 
concentrations in the range of 70 (3.9 mmol/l) to 110 mg/dl  (6.04 mmol/l). Inadequate 
secretion of insulin by the diabetic pancreas results in poor maintenance of the 
Normoglycemia with elevated blood glucose concentrations. The only treatment is with 
subcutaneous or intravenous insulin injections, traditionally administered in an open-loop 
manner. Without insulin treatment, these patients die. 
Hyperglycemia is known to induce insulin resistance and diabetes via increased 
blood glucose levels [22]. Hyperglycemia is considered when blood glucose exceeds 140 
mg/dl (7.8 mmol/l) after an Oral Glucose Tolerance Test, or 100 mg/dl (5.5 mmol/l) after 
a Fasting Glucose Tolerance Test. DCCT [22] state that the most of the long-term 
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complications associated with diabetes, such as nephropathy and retinopathy, result from 
sustained Hyperglycemia. In the United Kingdom Prospective Diabetes Study (UKPDS) 
[95] only 23% of patients allocated to diet alone attained fasting plasma glucose levels 
below 140 mg/dl.  
The persistent Hyperglycemia in diabetes is associated with long-term 
complications and dysfunction of various organs, especially the eyes, kidneys, nerves, 
heart, and blood vessels. 
On the other hand, Hypoglycemia will happen when the blood glucose level 
becomes less than 40 mg/dl (2.2 mmol/l) [49]. This condition is typically caused by the 
over-delivery of insulin ,and  it starves the body cells of fuel Hypoglycemia is a short-
term concern but it can lead to insulin shock as well as death. 
1.3. Types of diabetes 
Medical researchers have classified diabetes mellitus into two types: Type 1 
diabetes, or Insulin- Dependent Diabetes Mellitus (IDDM), and Type 2 diabetes, or Non 
Insulin Dependent Diabetes Mellitus (NIDDM), [(13), (16)].  
Type 1 diabetes is characterized by the patient’s immune system destroying the 
insulin- producing β-cells in the pancreas so that exogenous insulin is required to control 
the disease. This type commonly develops in young people (under 20 years old) and 
persists throughout life [95]. It may account for 5% to 10% of all diagnosed cases of 
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diabetes. It is believed that both genetic factors and virus infections cause this type of 
diabetes. Risk factors for type 1 diabetes include autoimmune, genetic, and 
environmental factors. DCCT [22] showed that an improved metabolic control was 
achieved by using intensive insulin treatment in Type 1 diabetes patients. 
Even more severe defects in insulin secretion are present in patients with type 1 
diabetes following islet transplantation, when Normoglycemia is maintained in the 
absence of exogenous insulin treatment [13]. This suggests that glucose homeostasis can 
be maintained despite significant loss of β-cell function when an individual has normal 
insulin sensitivity. 
Type 2 diabetes has been associated with defects in components of both the short-
term and chronic negative feedback loops [11]. Type 2 diabetes is a heterogeneous 
disorder characterized by insulin resistance and insulin deficiency due to a deficit in the 
mass of β cells, reduced insulin secretion, and resistance to the action of insulin [1]. The 
relative contribution and interaction of these defects in the pathogenesis of this disease 
remains to be clarified. About 90% to 95% of all diabetics are diagnosed with type 2 
diabetes. This type of diabetes is associated with older age, obesity, family history of 
diabetes, prior history of gestational diabetes, impaired glucose tolerance, physical 
inactivity, and race/ethnicity [10]. African Americans, Hispanic/Latino Americans, 
Native Americans, some Asian Americans, Native Hawaiian, and other Pacific Islanders, 
are at particularly high risk for type 2 diabetes. Type 2 diabetes is increasingly being 
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diagnosed in children and adolescents [10]. About 150 million individuals are estimated 
to have type 2 diabetes worldwide [1].  
Insulin-stimulated glucose disposal is reduced by 50-100% in patients with type 2 
diabetes as compared to non-diabetic controls. However, insulin resistance of a similar 
magnitude has been documented in many non-diabetic individuals including obese 
subjects, or during pregnancy, puberty, and aging [11]. Thus, Normoglycemia can be 
maintained in subjects with insulin resistance via increases in blood insulin levels. 
Defects of insulin secretion have been demonstrated in some people with type 2 diabetes 
[12].  
It was observed that the β-cell mass is reduced by 40-50% in patients with type 2 
diabetes when compared with weight-matched non-diabetic subjects [13]. In comparison, 
approximately 80-9 0 % of the β-cell mass is lost before the onset of hyperglycemia in 
individuals who develop type 1 diabetes, suggesting that a greater β-cell mass is required 
in the presence of insulin resistance. This is consistent with the observation of a 43% 
higher β-cell mass in Normoglycemia subjects with insulin resistance due to obesity. 
Although these data suggest that multiple defects are required for the onset of 
type 2 diabetes, it is unclear if these defects have a single causal origin or if they occur 
independently. Experimental induction of insulin resistance by using either high fat 
feeding, glucocorticoid administration, or genetically induced obesity has been shown to 
cause type 2 diabetes under certain circumstances. This supports the hypothesis that 
insulin resistance can cause β-cell defects, and hence diabetes, either by overworking the 
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β-cells or b y tox ic effects of h yp erglycemia on the β-cells. However, the existence of 
Normoglycemia in humans and animals highly resistant to insulin suggests that 
independent defects in insulin sensitivity and β-cell function are required for type 2 
diabetes [13]. 
Moreover, in Type 1 and Type 2 diabetes, some women can have glucose 
intolerance that is diagnosed during pregnancy. These types are common among obese 
women and women with a family history of diabetes. Gestational diabetes requires 
treatment during pregnancy period to normalize the maternal blood glucose levels to 
avoid complications in the infant. After pregnancy, 5% to 10% of women with 
gestational diabetes are found to have type 2 diabetes. Between 20% to 50% chance of 
developing diabetes in the next 5-10 years can happen with women who have had 
gestational diabetes [9].  
Other specific types of diabetes result from specific genetic conditions (such as 
maturity-onset diabetes of youth), surgery, drugs, malnutrition, infections, and other 
illnesses. Such types of diabetes may account for 1% to 5% of all diagnosed cases [9]. 
DCCT and UKPDS [95] demonstrated that tight glucose control reduces the risk 
of long term complications of type 1 and type 2 diabetes, thus reducing the cost to the 
health care system. There is no threshold for the relationship between blood glucose, 
Glycosylated Hemoglobin (HbA1C), and reduced risk. This indicates that glucose levels 
in subjects with type 1 or type 2 diabetes should be as close as possible to 
Normoglycemia.  
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It is estimated that nearly 50% subjects with type 2 diabetes will receive insulin at 
some stage of their disease [49]. 
1.4. Insulin Control 
The normal physiologic insulin secretion has two profiles:  
1) The basal secretion provides a background rate of insulin to the body. 
2) The meal related bolus secretion controls glucose level after having meals.  
The variables that indicate the basal insulin needs for an individual include growth and 
development, hormonal status, age, gender, stress levels, health status, and activity level. 
In addition, the amount and composition of food dictate the meal related needs [66].  
According to the present review surveys, the optimum treatment strategies for insulin 
treatment are used for type 1 diabetes. Insulin titration, or optimum insulin dosing, is a 
difficult task but is at the cornerstone of the management of type 1 diabetes [95]. DCCT 
has shown that intensive insulin therapy leads to improved outcomes of blood glucose 
control. On the other hand, DCCT showed that resources needed to achieve this goal are 
beyond the present means. Novel approaches are needed to assist patients with type 1 
diabetes and healthcare professionals in achieving the goals set by the DCCT. 
Information technology has an important role to play in contributing to these activities 
[21]. 
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Treatment of type 2 diabetes has received little attention from the adaptive control 
community except when titrating insulin dosing [95]. This may need revision given the 
complexities associated with the management of type 2 diabetes. It is usual to start the 
treatment of type 2 diabetes with non-pharmacological therapies. The base effort of these 
therapies is to improve glycaemic control and to begin the process of helping patients to 
make healthy life-style changes. Modification of the nutrition is the first step. If treatment 
goals are not achieved after a trial of dietary and life-style changes, an oral hypoglycemic 
is prescribed alone or in combination with insulin [21]. 
Even minor glucose elevations increase the risk of complications [24]. DCCT was the 
landmark study of 1440 type 1 diabetic people randomized into two treatment groups: 
intensive insulin delivery and standard care. Those people who had mean blood glucose 
concentrations below 110 mg/dl had no increase risk for retinopathy, nephropathy and 
peripheral vascular disease. Those patients with high glucose hemoglobin levels had a 
significant and positive correlation with increased risk [21]. However, when the blood 
glucose concentration was normalized, the risk of severe life-threatening hypoglycemia 
increased up to 10- fold above the risk in those patients with hyperglycemia. Thus the 
goal of achieving and maintaining normal blood glucose includes accepting the risk of 
hypoglycemia. A recent long-term study by the DCCT group has confirmed these 
conclusions. 
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1.5. Glucose Control in Healthy Individuals 
In the healthy individuals, the counter-regulatory hormone glucagon would be released in 
response to hypoglycemia to raise blood glucose concentration. However, the counter-
regulatory response in the diabetic patient is often blunted or absent, and hence it is less 
effective [90].  The exogenous factors that can affect the blood glucose concentration 
include food intake, rate of digestion, exercise, and reproductive state. It is therefore 
important to regulate diabetic patients' blood glucose concentrations to keep them within 
the Normoglycemia limits. 
As shown in Figure 1, the normal pancreas has two phases of insulin delivery: a first 
phase consisting of an immediate bolus and a second phase of prolonged insulin delivery 
[(49), (90)]. The function of the first phase is reduce the glucagon secretion from the 
pancreatic α cell and thus turn off the hepatic output of glucose, while the function of the 
second phase of insulin secretion is to metabolize the slower acting carbohydrates. The 
normal β cell has its first priority to prevent hyperglycemia. Thus the α cells are needed 
to secrete glucagon to prevent late postprandial hypoglycemia [90]. In summary, insulin 
and glucagon are secreted from β cells and α cells respectively.  
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Figure 1.1: Physiological glucose insulin regulatory system. [8] 
When the blood glucose concentration level is high, the β cells release insulin, which 
lowers the blood glucose concentration level by inducing the uptake of the excess glucose 
by the liver and other cells such as muscles, and by inhibiting hepatic glucose production 
[8]. The only way the β cell can respond to a falling  b lood  glucose concentration is to  
turn off the insulin secretion. There is no way the β cell can retract the insulin once it is 
given. 
When the blood glucose level is low, the α cells release glucagon, which results in 
increasing the blood glucose level by acting on liver cells and causing them to release 
glucose into the blood [8]. 
The β cell depends on the other counter- regulation hormones that should be secreted to 
buffer the falling glucose concentration. The hormones that play a major role in counter- 
regulation are glucagon, epinephrine, cortisol and growth hormone. This delicate balance 
is perfectly arranged to maintain the blood glucose within the Normoglycemia range [90]. 
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CHAPTER 2 
 
LITERATURE REVIEW 
                                
2.1 Introduction 
In this chapter, we present a survey of the literature on the modeling and control 
of insulin- glucose regulatory system. We will start by listing different models relevant to 
our work. The second section will present the different control strategies that have been 
considered. The advantages and weaknesses of each model will be considered. 
2.2 Mathematical Models 
Many mathematical models have been developed to better understand the 
mechanisms of the glucose insulin regulatory system. These models differ on the way in 
which they formulate and mimic the process. Each model has its own advantages and 
drawbacks, and each of them addresses a different aspect of the glucose-insulin 
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regulatory process. Types of models which have been used in the literature can be 
classified mathematically as:  
1- Ordinary differential equations (ODEs).  
2- Delay differential equations (DDEs).  
3- Partial differential equations (PDES).  
4- Stochastic differential equations (SDEs) . 
5- Integro-differential equations (IDEs).  
Different software packages can be used for different types of models for 
numerical analysis and simulations. 
2.2.1 Ordinary Differential Equations 
• Bergman Minimal Model 
This model depends on the measurements of the glucose level in the 
subcutaneous layer, so that the controller can decide and calculate the optimal 
amount of insulin to inject into the diabetes patient. In fact, several versions 
are used to model the patient ,and some of them are complex, but the 
following simplified version of Bergman’s widely used Minimal model 
[73,85,86] has five states:. 
𝑑𝑑𝑑𝑑
𝑑𝑑𝑡𝑡
= −𝑃𝑃1(𝑑𝑑 + 𝑑𝑑𝑏𝑏) − 𝑋𝑋𝑟𝑟𝑑𝑑 + 𝐷𝐷𝑚𝑚 (𝑡𝑡) 
13 
 
 
 
𝑑𝑑𝑋𝑋𝑟𝑟
𝑑𝑑𝑡𝑡
= −𝑃𝑃2𝑋𝑋𝑟𝑟 + 𝑃𝑃3(𝐼𝐼 − 𝐼𝐼𝑏𝑏) 
𝑑𝑑𝐼𝐼
𝑑𝑑𝑡𝑡
= −𝑛𝑛𝐼𝐼 + 𝑈𝑈(𝑡𝑡)
𝑉𝑉𝐼𝐼
                                         (2.1)  
𝑑𝑑𝑑𝑑𝑠𝑠𝑠𝑠
𝑑𝑑𝑡𝑡
= 𝑑𝑑 − 𝑑𝑑𝑠𝑠𝑠𝑠5 − 𝑅𝑅𝑢𝑢𝑡𝑡𝑢𝑢𝑛𝑛  
𝑑𝑑𝐷𝐷𝑚𝑚
𝑑𝑑𝑡𝑡
= −𝛼𝛼𝐷𝐷𝑚𝑚(𝑡𝑡)  
𝑥𝑥 =
⎣
⎢
⎢
⎢
⎡
𝑑𝑑
𝑋𝑋𝑟𝑟
𝐼𝐼
𝑑𝑑𝑠𝑠𝑠𝑠
𝐷𝐷𝑚𝑚⎦
⎥
⎥
⎥
⎤
⇒ ?̇?𝑥 =
⎣
⎢
⎢
⎢
⎢
⎡ ?̇?𝑑
𝑋𝑋?̇?𝑟
𝐼𝐼̇
𝑑𝑑𝑠𝑠𝑠𝑠̇
?̇?𝐷𝑚𝑚 ⎦
⎥
⎥
⎥
⎥
⎤
 
The system at the steady-state point is: 
𝑥𝑥𝑠𝑠 =
⎣
⎢
⎢
⎢
⎡
𝑑𝑑𝑏𝑏
𝑋𝑋𝑏𝑏𝑟𝑟
𝐼𝐼𝑏𝑏
𝑑𝑑𝑏𝑏𝑠𝑠𝑠𝑠
𝐷𝐷𝑏𝑏𝑚𝑚 ⎦
⎥
⎥
⎥
⎤ ,          𝑢𝑢𝑠𝑠 = 𝑛𝑛𝐼𝐼𝑏𝑏𝑉𝑉𝐼𝐼 ,           𝑑𝑑𝑠𝑠 = 0 
A very brief description of the five states; 
G:  Blood plasma glucose concentration above basal value (mg/dL). 
Xr:  Insulin in the remote compartment (mU/L). 
I (mU/L): Plasma insulin concentration above basal value. 
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Gsc: Glucose concentration on the subcutaneous layer. This state     
approximates G, and is the one which are measurable (mg/dL). 
Dm: Meal glucose disturbance (mg/dL/min). 
The elements in 𝑥𝑥𝑠𝑠 vector are basal values for the system. 
The manipulated insulin infusion rate (U(t); mU/min) is the input to 
the model. The time variable t is measured in minutes. The standard 
parameters which are usually used for the model can be found in Table 1 
which denotes the basal values for the system. 
Table 2.1: Bergman model parameters. 
Name Value 
𝑷𝑷𝟏𝟏 0.028735  min
-1 
𝑷𝑷𝟐𝟐 0.028335  min
-1 
𝑷𝑷𝟑𝟑 5.035.10
-5 mU/L 
n 5/54  min-1 
𝑽𝑽𝑰𝑰 12 L 
𝑹𝑹𝒖𝒖𝒖𝒖𝒖𝒖𝒖𝒖 0.7400mg/dL/min 
𝜶𝜶 0.05 
𝑮𝑮𝒃𝒃 81.3 mg/dL 
𝑿𝑿𝒃𝒃𝒃𝒃 0 
𝑰𝑰𝒃𝒃 15 mU/L 
𝑮𝑮𝒃𝒃𝒃𝒃𝒃𝒃 𝑑𝑑𝑏𝑏 − 5𝑅𝑅𝑢𝑢𝑡𝑡𝑢𝑢𝑛𝑛  
𝑫𝑫𝒃𝒃𝒃𝒃 0 
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To prevent the patient from going to the hyperglycemia or 
hypoglycemia level and to keep him or her in the normal situation , input and 
output constraints are required. Boundaries on the blood sugar level (output 
constraints) are required as follows: 
                   60 𝑚𝑚𝑚𝑚/𝑑𝑑𝑑𝑑  ≤ 𝑧𝑧 ≤ 180 𝑚𝑚𝑚𝑚/𝑑𝑑𝑑𝑑              (Where z is the measured variable). 
The input constraints restrict the rate and the variations of possible 
injected insulin, and so that system can work within physiological and 
physical limits. The chosen constraints are shown below: 
0 𝑚𝑚𝑈𝑈/𝑚𝑚𝑚𝑚𝑛𝑛 ≤ 𝑢𝑢  ≤ 100 𝑚𝑚𝑈𝑈/𝑚𝑚𝑚𝑚𝑛𝑛 
−16.7 𝑚𝑚𝑈𝑈/𝑚𝑚𝑚𝑚𝑛𝑛 ≤ ∆𝑢𝑢 ≤ 16.7 𝑚𝑚𝑈𝑈/𝑚𝑚𝑚𝑚𝑛𝑛 
The system of differential equations can be set up as follows: 
?̇?𝑋 = ?̅?𝐴𝑋𝑋 + 𝐵𝐵�𝑈𝑈 + 𝐸𝐸�𝐷𝐷 
where X, U and D are incremental variables, X = x - xs, U = u - us and 
D = d - ds
where X is the state vector, U is the input variable for insulin injection, and D 
is the input variable for meal consumption considered as meal disturbance. 
The matrices ?̅?𝐴,𝐵𝐵 ,𝐸𝐸  are the partial derivatives of the model: 
. 
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?̅?𝐴 =
⎣
⎢
⎢
⎢
⎡
−𝑃𝑃1 − 𝑋𝑋𝑟𝑟 −𝑑𝑑𝑏𝑏 0 0 10 −𝑃𝑃2 𝑃𝑃3 0 00 0 −𝑛𝑛 0 00.2 0 0 −0.2 00 0 0 0 −𝛼𝛼⎦⎥⎥
⎥
⎤
 
𝐵𝐵� = [0 0 1
𝑉𝑉𝑡𝑡
0 0]𝑇𝑇 
𝐸𝐸� = [1 0 0 0 −𝛼𝛼]𝑇𝑇 
However, the Bergman minimal model has two main disadvantages: 
1. Highly ill-posed inverse problem.  
2. Glucose kinetics are mostly reconstructed by deterministic iterative 
numerical algorithms which might be not accurate. 
• Six-dimensional ODE model 
This model is based on two negative feedback loops which describe 
the effects of insulin on glucose utilization and production and the effect of 
glucose on insulin secretion. Sturis et al. (1991) [46] developed a six-
dimensional ODE model which is the basis of several DDE models [5, 52, 45, 
20].   
The model is described by the following system of nonlinear ODE: 
𝑑𝑑𝑑𝑑(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑑𝑑𝑚𝑚𝑛𝑛 − 𝑓𝑓2�𝑑𝑑(𝑡𝑡)� − 𝑓𝑓3�𝑑𝑑(𝑡𝑡)�𝑓𝑓4(𝐼𝐼𝑚𝑚(𝑡𝑡) + 𝑓𝑓5�𝑥𝑥3(𝑡𝑡)�, 
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𝑑𝑑𝐼𝐼𝑝𝑝(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑓𝑓1�𝑑𝑑(𝑡𝑡)� − 𝐸𝐸 �𝐼𝐼𝑝𝑝(𝑡𝑡)𝑉𝑉𝑝𝑝 − 𝐼𝐼𝑚𝑚(𝑡𝑡)𝑉𝑉𝑝𝑝 � − 𝐼𝐼𝑝𝑝(𝑡𝑡)𝑡𝑡𝑝𝑝  
                                        𝑑𝑑𝐼𝐼𝑚𝑚(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝐸𝐸 �𝐼𝐼𝑝𝑝 (𝑡𝑡)
𝑉𝑉𝑝𝑝
−
𝐼𝐼𝑚𝑚(𝑡𝑡)
𝑉𝑉𝑝𝑝
� −
𝐼𝐼𝑝𝑝 (𝑡𝑡)
𝑡𝑡𝑚𝑚
                               (2.2) 
𝑑𝑑𝑥𝑥1(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 3
𝑡𝑡𝑑𝑑
(𝐼𝐼𝑝𝑝(𝑡𝑡) − 𝑥𝑥1(𝑡𝑡)) 
𝑑𝑑𝑥𝑥2(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 3
𝑡𝑡𝑑𝑑
(𝑥𝑥1(𝑡𝑡) − 𝑥𝑥2(𝑡𝑡)) 
𝑑𝑑𝑥𝑥3(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 3
𝑡𝑡𝑑𝑑
(𝑥𝑥2(𝑡𝑡) − 𝑥𝑥3(𝑡𝑡)) 
Toli´c et al. [44] simplified the previous model by using only linear or up 
to second-order terms in the Taylor expansions of the functions 
𝑓𝑓1 , 𝑓𝑓2 , 𝑓𝑓3,𝑓𝑓4  & 𝑓𝑓5  and they were able to show similar numerical results. 
Where  
                                              f1(G) = Rm/ (1+exp((C1-G/Vg)/a1))                               (2.3) 
is a function which models the production of pancreatic insulin as 
controlled by the glucose concentration. 
f2(G) = Ub(1-exp(-G/(C2Vg))),                                       
(2.4) 
18 
 
 
 
             is a function for glucose utilization by brain and nerves. 
                                        f3(G) = G/(C3Vg);                                                                  (2.5) 
                              f4(I) = U0+(Um-U0)/(1+exp(-β ln(I/C4(1/Vi+1(Eti
 𝑓𝑓3�𝑑𝑑(𝑡𝑡)�𝑓𝑓4(𝐼𝐼(𝑡𝑡) stands for insulin-dependent utilization/uptake by muscle, 
fat cells and others. This  insulin-dependent glucose utilization is 
accomplished by the so-called ‘‘remote insulin’’. 
                                        f R5R(I) = RRgR/(1+exp(α(I/VRpR-CR5R)))                                            (2.7) 
is a function modeling hepatic glucose production. Table 2.2 lists the 
different parameters in the model and their nominal values. 
 
Table 2.2:  Functions parameters values 
Parameters Units Values Parameters Units Values 
𝑽𝑽𝒈𝒈  1 10 𝑈𝑈0 mg. minP-1 40 
𝑹𝑹𝒃𝒃 𝜇𝜇UminP
-1 210 𝑈𝑈𝑚𝑚  mg. minP
-1 940 
𝒂𝒂𝟏𝟏 mg.1P
-1 300 𝛽𝛽  1.77 
𝑪𝑪𝟏𝟏 mg.1P
-1 2000 𝐶𝐶4 𝜇𝜇U1 P-1 80 
𝑼𝑼𝒃𝒃 mg. minP
-1 72 𝑅𝑅𝑚𝑚  mg. minP
-1 180 
𝑪𝑪𝟐𝟐 mg.1P
-1 144 𝛼𝛼 𝑢𝑢𝜇𝜇U1 P-1 0.29 
𝑪𝑪𝟑𝟑 mg.1P
-1 1000 𝐶𝐶5 𝜇𝜇U1 P-1 26 
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𝒖𝒖𝒑𝒑 
)))))                   
(2.6) 
min 6 E 1min 0.2 -1 
𝒖𝒖𝒊𝒊 min 100 𝑡𝑡𝑑𝑑  min 36 
𝑽𝑽𝒑𝒑 1 3 𝑉𝑉𝑚𝑚  1 11 
This model can be considered generic because it describes various aspects of 
glucose-insulin regulation. However, this model does not produce self-sustaining 
oscillation which is a major characteristic of this system [14]. 
2.2.2. Models in the form of integral-differential equations 
One of the main reasons to introduce integral-differential models is that 
the widely used minimal model lacks a proper qualitative behavior because its 
time lag equals the basal glucose level Gb
                                     𝑑𝑑𝐼𝐼(𝑡𝑡)
𝑑𝑑(𝑡𝑡) = −𝑏𝑏2𝐼𝐼(𝑡𝑡) + 𝑏𝑏6𝑏𝑏5 ∫ 𝑑𝑑(𝑠𝑠)𝑑𝑑𝑠𝑠𝑡𝑡𝑡𝑡−𝑏𝑏5                                   (2.8) 
. De Gaetano and Arino [3, 4] modified 
the minimal model and formulated a delay integro differential equation model 
which can be considered closer to real representation of the insulin- glucose 
system:  
𝑑𝑑𝑑𝑑(𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑏𝑏1𝑑𝑑(𝑡𝑡) − 𝑏𝑏4𝐼𝐼(𝑡𝑡)𝑑𝑑(𝑡𝑡) + 𝑏𝑏7 
        𝑑𝑑(𝑡𝑡) = 𝑑𝑑𝑏𝑏  , 𝑡𝑡 ∈ [−𝑏𝑏5, 0],𝑑𝑑(0) = 𝑑𝑑𝑏𝑏 + 𝑏𝑏0, 𝐼𝐼(0) = 𝐼𝐼𝑏𝑏 + 𝑏𝑏3𝑏𝑏0 
 where : 
t  is time [ min]. 
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G  is the  glucose plasma concentration [mg/dl]. 
Gb is the basal (preinjection) plasma glucose concentration [mg/dl]. 
I  is the insulin plasma concentration. 
Ib is the basal (preinjection) insulin plasma concentration [pM]. 
b0 is the theoretical increase in plasma concentration over basal glucose 
concentration at time zero after instantaneous administration and redistribution of 
the IV  glucose bolus [mg/dl]. 
b1 is the spontaneous glucose first order disappearance rate constant [min-1]. 
b2 is the apparent "1st-order disappearance rate constant for insulin [min-1]. 
b3 is the 1st-phase insulin concentration increase per (mg/dl) increase in the 
concentration of glucose at time zero due to the injected bolus [pM/(mg/dl)]. 
b4 is the constant amount of insulin-dependent glucose disappearance rate 
constant per pM of plasma insulin concentration [min-1 pM-1]. 
b5 is a delay that represents the length of the past period whose plasma glucose 
concentrations influence the current pancreatic insulin secretion [min]; 
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b6  is the constant amount of second-phase insulin release rate per (mg/dl) of 
average plasma glucose concentration throughout the previous b5 minutes [min-1 
pM/ (mg/dl)]. 
b7
• Glucose concentration changes in blood depend on: 
 is the constant increase in plasma glucose concentration due to constant 
baseline liver glucose release [(mg/dl) min1]. 
This model describes better the Glucose-Insulin system by taking into account the 
following aspects: 
(1) Spontaneous, insulin-independent net glucose tissue uptake.  
(2) Insulin-dependent net glucose tissue uptake, which means that 
changes in tissue glucose uptake and in liver glucose delivery are 
considered together.  
 (3) Constant baseline liver glucose production.  
• Insulin plasma concentration changes depend on:  
                         (1) Spontaneous constant-rate decay because of insulin catabolism,  
                         (2) Pancreatic insulin secretion.  
The second right-hand-side term in 𝑑𝑑𝐼𝐼(𝑡𝑡)
𝑑𝑑(𝑡𝑡)   is a delay term that refers to the 
pancreatic secretion of insulin. Effective pancreatic secretion (after the liver 
first-pass effect) at time t is proportional to the average value of glucose 
concentration in the b5 minutes preceding time t. Because of delay, the glucose 
level must be specified both at time zero and at times [- b5, 0]. 
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In their attempt to extend this model and to make it more generic Li et al [45] 
introduced the following changes: 
𝑑𝑑𝑑𝑑(𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑓𝑓�𝑑𝑑(𝑡𝑡)� − 𝑚𝑚(𝑑𝑑(𝑡𝑡), 𝐼𝐼(𝑡𝑡)) + 𝑏𝑏7 
                                    𝑑𝑑𝐼𝐼 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑝𝑝�𝐼𝐼(𝑡𝑡)� + 𝑞𝑞(𝑑𝑑(𝑑𝑑𝑡𝑡))                                   (2.9) 
  where 
𝑑𝑑(0) = 𝑑𝑑𝑏𝑏 + 𝑏𝑏0, 𝐼𝐼(0) = 𝐼𝐼𝑏𝑏 + 𝑏𝑏3𝑏𝑏0,𝑑𝑑(𝑡𝑡) = 𝑑𝑑𝑏𝑏 , 𝑡𝑡 ∈ [−𝑏𝑏5 , 0],𝑑𝑑𝑡𝑡(𝜃𝜃) = 𝑑𝑑(𝑡𝑡 + 𝜃𝜃),
𝑡𝑡 > 0,𝜃𝜃 ∈ [−𝑏𝑏5, 0] 
Since this model is generic, so that, J. Li [45]:, define  L(Gt )  for  two special 
cases: 
    𝑑𝑑(𝑑𝑑𝑡𝑡 ) = 𝑑𝑑(𝑡𝑡 − 𝑏𝑏5)                                                (2.10) Case I: 
𝑑𝑑𝑑𝑑 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑏𝑏1𝑑𝑑(𝑡𝑡) − 𝑏𝑏4𝐼𝐼(𝑡𝑡)𝑑𝑑(𝑡𝑡)𝛼𝛼𝑑𝑑 (𝑡𝑡)+1 + 𝑏𝑏7                     (2.11) 
𝑑𝑑𝐼𝐼 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑏𝑏2𝐼𝐼(𝑡𝑡) + 𝑏𝑏6𝑑𝑑(𝑡𝑡 − 𝑏𝑏5)  
UCase II: 
𝑑𝑑(𝑑𝑑𝑡𝑡 ) = 1𝑏𝑏5 � 𝑑𝑑(𝑡𝑡 + 𝜃𝜃)𝑑𝑑𝜃𝜃0−𝑏𝑏5  
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                                      𝑑𝑑𝑑𝑑 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑏𝑏1𝑑𝑑(𝑡𝑡) − 𝑏𝑏4𝐼𝐼(𝑡𝑡)𝑑𝑑(𝑡𝑡)𝛼𝛼𝑑𝑑 (𝑡𝑡)+1 + 𝑏𝑏7                      (2.12) 
𝑑𝑑𝐼𝐼(𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑏𝑏2𝐼𝐼(𝑡𝑡) + 𝑏𝑏6𝑏𝑏5 � 𝑑𝑑(𝑡𝑡 + 𝜃𝜃)𝑑𝑑𝜃𝜃0−𝑏𝑏5  
The author (J. Li) assumed that the insulin-dependent glucose uptake follow the 
Michaelis–Menten form because of a physical constraint which allows a unit of 
insulin to handle  only a limited amount of glucose in a unit of time.  Both 
analysis and numerical simulations are mostly based on the assumption that the  
insulin dependent net glucose tissue uptake follows Michaelis–Menten dynamics 
with 1/α as the half-saturation constant.  
However, this assumption makes the mass action law in this situation less 
realistic. 
𝑑𝑑𝑑𝑑 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= Glucose production - Glucose utilization, 
     𝑑𝑑𝐼𝐼(𝑡𝑡)
𝑑𝑑𝑡𝑡
= Insulin production - Insulin clearance. 
To address this issue Mukhopadhyay et al. [6] proposed the following 
modifications: 
𝑑𝑑𝑑𝑑 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑏𝑏1𝑑𝑑(𝑡𝑡) − 𝑏𝑏4𝐼𝐼(𝑡𝑡)𝑑𝑑(𝑡𝑡) + 𝑏𝑏7         (2.13)  
𝑑𝑑𝐼𝐼 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= −𝑏𝑏2𝐼𝐼(𝑡𝑡) + 𝑏𝑏6 ∫ 𝑤𝑤(𝑠𝑠)𝑑𝑑(𝑡𝑡 − 𝑠𝑠)𝑑𝑑𝑠𝑠∞0  
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where:  𝑑𝑑(𝑡𝑡) = 𝑑𝑑𝑏𝑏 , 𝑡𝑡 ∈ (−∞, 0),𝑑𝑑(0) = 𝑑𝑑𝑏𝑏 + 𝑏𝑏0, 𝐼𝐼(0) = 𝐼𝐼𝑏𝑏 + 𝑏𝑏3𝑏𝑏0 
𝑤𝑤(𝑠𝑠) = 𝛼𝛼2𝑠𝑠 𝑒𝑒−𝛼𝛼𝑠𝑠   [6]. 
2.2.3. Models in the form of partial differential equations 
Many models in the form of PDEs exist. For example, Boutayeb and 
Derouich [2], Boutayeb and Twizell [1], Aslanidi et al. [74], Bertram and 
Pernarowski [82] (reaction–diffusion type related to the Langerhans islets) , Wach 
et al. [76] are all PDE models. In particular, Wach et al assumed that Injected 
soluble insulin is present in the subcutaneous tissue in hexametric and diametric 
form and only diametric molecules can penetrate the capillary membrane: 
𝜕𝜕ℎ
𝜕𝜕𝑡𝑡
= 𝑃𝑃(𝑄𝑄𝑑𝑑3 − ℎ) + 𝐷𝐷∇2h , 
                           𝜕𝜕𝑑𝑑
𝜕𝜕𝑡𝑡
= − 𝑃𝑃(𝑄𝑄𝑑𝑑3 − ℎ) + 𝐷𝐷∇2h − Bd                             (2.14) 
where h, d are concentrations of hexametric and diametric insulin, P is a rate 
constant, Q is a chemical equilibrium constant, D is a diffusion constant, and B is 
an absorption rate constant. Wach et al solve numerically the system of PDE, and 
they divided the subcutaneous region into spherical shells for the space 
discretization. 
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2.2.4.  Models in the form of delay differential equations (DDEs): 
These models takes into consideration the effect of time delay in the 
Insulin –Glucose system allowing DDEs model to mimic the real situation and 
make them more realistic than the previous models. Several models were 
formulated in the form of DDEs based on the model by Sturis et al (1991) [46]. 
One of these models was formulated by K. Engelborghs [52], in which the 
glucose triggered insulin production delay is ignored: 
𝑑𝑑𝑑𝑑(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑑𝑑𝑚𝑚𝑛𝑛 − 𝑓𝑓2�𝑑𝑑(𝑡𝑡)� − 𝑓𝑓3�𝑑𝑑(𝑡𝑡)�𝑓𝑓4�𝐼𝐼(𝑡𝑡)� + 𝑓𝑓5�𝐼𝐼(𝑡𝑡 − 𝜏𝜏2)� 
                                                𝑑𝑑𝐼𝐼 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑓𝑓1�𝑑𝑑(𝑡𝑡)� − 𝐼𝐼(𝑡𝑡)𝑡𝑡1                             (2.15) 
However, insulin production stimulated by glucose time delay is missing. We 
made another trial to model the exogenous insulin infusion by using the same 
internal insulin production function form which was considered to be too 
artificial. 
                 𝑑𝑑𝑑𝑑 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑑𝑑𝑚𝑚𝑛𝑛 − 𝑓𝑓2�𝑑𝑑(𝑡𝑡)� − 𝑓𝑓3�𝑑𝑑(𝑡𝑡)�𝑓𝑓4�𝐼𝐼(𝑡𝑡)� + 𝑓𝑓5�𝐼𝐼(𝑡𝑡 − 𝜏𝜏2)�             (2.16) 
𝑑𝑑𝐼𝐼(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝛼𝛼𝑓𝑓1(𝑑𝑑(𝑡𝑡)) − 𝐼𝐼(𝑡𝑡)𝑡𝑡1 + (1 − 𝛼𝛼)𝑓𝑓1(𝑑𝑑(𝑡𝑡 − 𝜏𝜏1)) 
Li et al. (2005) [49] proposed another model, known as the two time delay model. 
It includes time delay in the insulin response to the glucose stimulation: 
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                𝑑𝑑𝑑𝑑 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑑𝑑𝑚𝑚𝑛𝑛 − 𝑓𝑓2�𝑑𝑑(𝑡𝑡)� − 𝑓𝑓3�𝑑𝑑(𝑡𝑡)�𝑓𝑓4�𝐼𝐼(𝑡𝑡)� + 𝑓𝑓5�𝐼𝐼(𝑡𝑡 − 𝜏𝜏2)�                    (2.17) 
𝑑𝑑𝐼𝐼(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑓𝑓1�𝑑𝑑(𝑡𝑡 − 𝜏𝜏1)� − 𝑑𝑑𝑚𝑚𝐼𝐼(𝑡𝑡) 
Where the initial condition I (0) = I0 > 0, G (0) = G0 > 0, G (t) ≡ G0  for all t ∈ 
[−τ1, 0] and I (t) ≡ I0 for t ∈ [−τ2, 0] with τ1, τ2 > 0.  
τ1 is the time delay of insulin production stimulated by glucose, τ2 is the time 
delay of hepatic glucose production and di
2.2.5. Stochastic Models: 
  is the insulin degradation rate. This 
model proved to be a possible mechanism to explain the origin of ultradian 
(recurrent periods or cycles repeated throughout a 24-hour) oscillations in 
pancreatic insulin secretion. 
 
Because of the practical limitations, the new algorithms are developed mainly to 
analyze the blood glucose level (BGL) time series (TS). This time series is 
decomposed into a cyclic component to describe the daily pattern and a trend 
component to express the BGL long term variations. 
For treatment with Insulin to be satisfactory, the trend component should be 
almost constant lies in the normal range, while the cyclic component varies within 
acceptable limits.  
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To evaluate the variability BGL standard deviation or the mean amplitude of 
glycemic excursions (MAGE) may be calculated [25]. However, it is better to use 
the  instantaneous index to describe the variability of BGL. 
The stochastic volatility (SV) model was used to capture the randomness of the 
data. However, the SV model is difficult to estimate because of its nonlinear 
structure. Nonlinear estimation methods, such as Markov chain Monte Carlo 
(MCMC) algorithms , solve this problem partially [23]–[33]. 
Recent research by Paolo Magni (2006) used the SV model literature: 
𝑦𝑦𝑚𝑚 =  𝑡𝑡𝑚𝑚 + 𝜎𝜎𝑚𝑚𝜖𝜖𝑚𝑚         , 𝑚𝑚 = 1, … … ,𝑁𝑁                                          (2.18) 
 
The trend can be described by means of an integrated random walk model: 
                     𝑡𝑡𝑚𝑚 = 𝑡𝑡𝑚𝑚−1 + 𝑠𝑠𝑚𝑚−1                                                     (2.19) 
𝑠𝑠𝑚𝑚 = 𝑠𝑠𝑚𝑚−1 + 𝑤𝑤𝑚𝑚−1   , 𝑚𝑚 = 2, … … ,𝑁𝑁                                                (2.20) 
with  𝑡𝑡𝑚𝑚 , 𝑠𝑠𝑚𝑚  initial conditions, and where 𝑤𝑤𝑚𝑚    is the random fluctuation of the trend. 
It is more convenient to use the logarithm of volatility since volatility is non- 
negative,  
 ℎ𝑚𝑚 = ln⁡( 𝜎𝜎𝑚𝑚2) , the stochastic model becomes:  
ℎ𝑚𝑚 = ℎ𝑚𝑚−1 + 𝑢𝑢𝑚𝑚−1   , 𝑚𝑚 = 2, … . . ,𝑁𝑁                                                           (2.21) 
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with  ℎ1 initial condition and where 𝑢𝑢𝑚𝑚  are the random fluctuations of the log-
volatility. 
Let us denote  𝑡𝑡 =  [ 𝑡𝑡1 … 𝑡𝑡𝑀𝑀]𝑇𝑇  ,  𝑧𝑧 = [𝑡𝑡1 𝑠𝑠1 𝑤𝑤1 … 𝑤𝑤𝑁𝑁−2]𝑇𝑇 
𝐻𝐻𝑧𝑧 =
⎣
⎢
⎢
⎢
⎢
⎡
1 0 0 0 … 01 1 0 0 … 01 2 1 0 … 01 3 2 1 … 0
⋮ ⋮ ⋮ ⋮ ⋱ ⋮1 𝑁𝑁 − 1 𝑁𝑁 − 2 𝑁𝑁 − 3 … 1⎦⎥⎥
⎥
⎥
⎤
 
               The trend model: 
                                                𝑡𝑡 = 𝑑𝑑𝐻𝐻𝑧𝑧𝑧𝑧                                               (2.22) 
where  𝑑𝑑  is a matrix that takes into account the missing measurement. 
ℎ =  [ ℎ1 … ℎ𝑀𝑀]𝑇𝑇  ,  𝑥𝑥 = [ℎ1 𝑢𝑢1 𝑤𝑤1 … 𝑢𝑢𝑁𝑁−1]𝑇𝑇 
𝐻𝐻𝑥𝑥 = �1 0 … 01 1 … 0⋮ ⋮ ⋱ ⋮1 1 … 1� 
The volatility model can be rewritten as: 
                                               ℎ = 𝑑𝑑𝐻𝐻𝑥𝑥𝑥𝑥                                                       (2.23) 
One of the important points of this model is that it uses simultaneous 
identification techniques to calculate the trend and the volatility instead of known 
ones. However, this model is valid on a fixed time grid which manages missing 
data and ignores spot measurement, which may result in underestimating the 
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variability. The simulation results of this research are promising from a medical 
point of view.   
2.3.  Control Algorithms 
The challenge of automating insulin delivery for diabetic patients by using implantable 
pumps and glucose sensors has received considerable attention over the last 10-20 years. 
Recent surveys and tutorials provide excellent overviews of diabetes control strategies 
from a control engineering perspectives, some of these techniques are described in the 
following sections.  
2.3.1.   PID/PD controller 
Several control algorithms have been used since 1960 in medical treatment to 
inject both glucose and insulin to control the glucose level in the diabetes patient. 
On-off control and Biostator are examples of these techniques, B.W. Bequette 
[11].  Several work are using Biostator by (GCIIS), Fabietti PG, Massi Benedetti 
M-1991[25] ,and later to the “Biostator” algorithm and device of Clemens , 
Brunetti P, Cobelli C, Cruciani P-1993 [17]. This controller uses a low-volume 
continuous-flow blood glucose sampling mechanism with a dual infusion system 
(insulin and dextrose) to maintain blood glucose concentration at the desired 
value. The control algorithm used was a nonlinear proportional-derivative (PD) 
structure, using a five-point moving average of glucose measurements to 
minimize noise effects. However, dual delivery system (insulin & glucose) is 
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difficult because of reservoir's additional size, and it did not show good results in 
medical treatment for diabetic patients.  
Therefore , researchers considered only insulin  injection in their algorithms. They 
used standard or modified PID control algorithms with some enhancement to the 
feedback control (such as feed forward action) to compensate for the meal 
disturbance. The calculation is performed by assuming that the meal time and 
content are known.  However, PD controller was used more often in the previous 
research and preferred on PID controller to avoid the integral action which may 
result in insulin overdosing (Wind up) which, in turn, may cause hypoglycemia 
during and after the meals period. 
The windup problem can be overcome or mitigated by using “anti-reset windup” 
with the integral control action.  
The proposed PID controllers were evaluated in simulation studies of post-
prandial responses. A few were evaluated by using applications to dogs or 
humans in experimental conditions (e.g., intravenous vs. subcutaneous sensors 
and pumps, different types of insulin and insulin analogs, etc.). 
2.3.2.  Model Predictive Control (MPC): 
A model-based control strategy with model predictive control (MPC) is one of 
the control algorithms most used in recent years [53]. In fact, MPC is used to treat 
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diabetes patients for the same reasons that it has been very successful in the 
process industries: 
(i) It can be used to control both linear and nonlinear processes. So, both 
linear and nonlinear models can be used. 
(ii) It can handle inherent inequality constraints. 
(iii) It can predict future behavior. 
(iv) Model parameters can be easily updated. 
 
Figure 2.1: Model Predictive controller (MPC). 
 
 
MPC objective function: 
𝐽𝐽 = ∑ (𝑟𝑟𝑘𝑘+𝑚𝑚𝑃𝑃𝑚𝑚=1 − 𝑦𝑦�𝑘𝑘+𝑚𝑚)2 + 𝜆𝜆∑ Δ𝑢𝑢𝑘𝑘+𝑚𝑚−12𝑀𝑀𝑚𝑚=1                                                                                      
(2.24) 
where: 
J   Objective function. 
P   prediction horizon. 
M   the control horizon. 
K   the sample time index. 
𝜆𝜆   Weight on the manipulated input. 
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Δu  The manipulated input increment. 
𝑦𝑦�  The predicted output. 
r   the desired setpoint. 
A key issue is the availability of a dynamic model that is reasonably accurate for 
the current patient conditions. The evaluations for diabetes control problems using 
MPC technique have shown that glucose control can be improved in comparison 
with conventional PID control strategies.  
In 1999, Parker et al were the first to publish an MPC approach to manage the 
glucose levels in type 1 diabetic patients. Their research was a simulation study 
that used the Sorensen (1985) model as the “virtual patient” [84,85]. They used 
the following approaches to develop the model: 
i. Direct identification from patient data using rich signals. 
ii. Reduced order numerical models derived from the original 
compartmental model.  
iii. Linearized versions of the compartmental model coupled with a 
state estimator.  
The state estimator was used to estimate unmeasured meal disturbance, providing 
a form of feed-forward control without the need for direct knowledge of the meal. 
They also performed online estimation of the key physiologic parameters by using 
a Kalman filter. 
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In Parker’s simulation studies, the MPC with state estimation showed the 
following results: 
1) The meals disturbance can be compensated without the direct knowledge of 
meal timing and/or content.  
2) The blood glucose levels were controlled well and they settled within normal 
range.  
3)  This technique was tested for measurement noise and patient uncertainty 
(parametric uncertainty) it is also managed, including estimation of key patient 
parameters.  
However, the disadvantage of MPC is that it requires a good model that almost 
matches the real process in patients.  This is a difficult requirement because the 
model parameters depend, e.g., on the age, weight, health of the patient. So, these 
parameters differ from patient to patient and they are affected by the patient 
conditions such as anger, sleep, sport, which are reflected in the  glucose level in 
the blood.   
 MPC has not been tested in detailed clinical trials involving multiple meals but 
the system including the pump and controller is used for certain cases only, and 
the controller and model parameters should be tuned for each patient. 
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2.3.3.  Run-to-Run Control: 
Run-to-run control  is a technique which deals with the systems that show cyclic 
behavior, K. S. Lee & J. H. Lee, et al [53]. The main idea in this technique is that 
certain disturbances are persistent across repeated cycles in a process. So, this 
technique avoids the repetition of corrective action to compensate for such 
disturbances and it formulates an update on a time scale of the entire cycle which 
necessitates only one correction at the end of each batch and in each cycle the 
control action is refined more until nearly perfect control is achieved. This type of 
control is also called iterative learning control (ILC) which minimizes the effect 
of the persistent disturbance over multiple cycles.   
The control strategy is also based on a measurement , unlike other techniques 
which are model- based and its independent variable of the control loop is the 
batch number, as shown in B. Srinivasan, C.J. Primus, et al [9] & C. Owens, H. 
Zisser [18]. The Run-Run algorithm can be summarized as follows: 
1. The input profile is parameterized for k  run, uk(t), as U(t, vk). by 
considering the ψk   as a sample version of the measured output yk(t) such 
that both input parameter vector vk  and sample output ψk  (controlled 
variable). 
ψk = F(vk)  
2. Choose an initial guess for vk   , k = 1. 
35 
 
 
 
3. Complete the run by using the  uk(t)  corresponding to  vk . Determine ψk  
from the measurement yk(t). 
4. Input parameters are updated by using the following formula  vk+1 = vk + K(ψΓ − ψk)                                                                   (2.25)                                                                             
 
where: K: appropriate gain matrix. 
ψk:  The reference value. 
Then, set k = k + 1. And repeat 3, 4 steps until the algorithm converges. 
Thus a solution is implemented as an open-loop strategy for each batch (24 hour 
cycle), and the feedback allows refinement over successive batches (days).  The 
advantage of this technique is that it is almost independent because it translates 
the limited information about glucose level in the patient into any time of 
particular interest. In the present context, the limited measurement information of 
the patient's blood glucose level is translated into quality measurements (max/min 
glucose) and the resultant quality variables are of the same type of variables that 
are used to evaluate the effectiveness of a particular insulin regimen. 
The results of the clinical trial in H. Zisser, L. Jovanovic, F.J. Doyle III [36], 
showed that most of the patients responded positively to the algorithm, and the 
algorithm’s predictions were in line with the medical doctors’ recommendations. 
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2.3.4.  Pole Placement Strategy: 
During an oral glucose load, the relationship between plasma insulin and blood 
glucose concentration in a normal subject has been described by the following 
proportional derivative control law: 
𝐼𝐼(𝑡𝑡) =  𝑎𝑎𝑑𝑑(𝑡𝑡) + 𝑏𝑏 𝑑𝑑𝑑𝑑 (𝑡𝑡)
𝑑𝑑𝑡𝑡
+ 𝑠𝑠                                                                           (2.26) 
where 
𝐼𝐼 is the plasma insulin concentration;  
G is the blood glucose concentration;  
a, b, and c are the parameters responsible for insulin secretion.  
Hashiguchi Y, Sakakida-1994 [38] have estimated the parameter values by using 
the nonlinear least squares method. Figure 3 illustrate the medical explanation of 
the subcutaneous-injected insulin by the three-compartment linear model of:  
𝑑𝑑𝑋𝑋 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝐼𝐼𝐼𝐼𝑅𝑅(𝑡𝑡) − 𝑢𝑢𝑋𝑋(𝑡𝑡)                                                                                 (2.27)  
𝑑𝑑𝑑𝑑 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑢𝑢𝑋𝑋(𝑡𝑡) − (𝑝𝑝 + 𝑜𝑜)𝑑𝑑(𝑡𝑡)                                                                        (2.28) 
𝑑𝑑𝑑𝑑(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑝𝑝𝑑𝑑(𝑡𝑡) − 𝑛𝑛𝑑𝑑(𝑡𝑡)                                                                                  (2.29)  
𝐼𝐼(𝑡𝑡) = 𝑑𝑑(𝑡𝑡)
𝑉𝑉
                                                                                               (2.30) 
where  
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𝐼𝐼𝐼𝐼𝑅𝑅 is the insulin infusion rate. 
𝑋𝑋, 𝑑𝑑, and 𝑑𝑑 are the insulin masses in the two subcutaneous compartments and in 
plasma, respectively; 
V is plasma volume.  
 
Figure 2.3: The compartmental model of SC insulin absorption and kinetics for pole placement strategy. 
with data obtained in ten diabetic subjects treated with both regular and Lispro 
insulin, the model parameters have been estimated by nonlinear least squares. The 
requirement is to have the plasma insulin concentration of the diabetic subject to 
follows the same dynamics of the normal subject. This control law is obtained by 
substituting equation 2.26 into equation 2.27, and neglecting higher order 
derivatives such that: 
𝐼𝐼𝐼𝐼𝑅𝑅(𝑡𝑡) = 𝐾𝐾𝑝𝑝𝑑𝑑(𝑡𝑡) + 𝐾𝐾𝑑𝑑 𝑑𝑑𝑑𝑑 (𝑡𝑡)𝑑𝑑𝑡𝑡 + 𝐾𝐾𝑠𝑠                                                              (2.31)  
where  
𝐾𝐾𝑝𝑝 = 𝑎𝑎𝑚𝑚𝑛𝑛𝑉𝑉𝑝𝑝  
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𝐾𝐾𝑑𝑑
𝐾𝐾𝑝𝑝
= 1
𝑢𝑢
+ 1
𝑚𝑚
+ 1
𝑛𝑛
+ 𝑏𝑏
𝑎𝑎
 
𝐾𝐾𝑠𝑠 = 𝑑𝑑 + 𝑠𝑠𝑎𝑎 𝐾𝐾𝑝𝑝  
𝑚𝑚 = 𝑜𝑜 + 𝑝𝑝,  
𝑑𝑑 accounts for the IV (intravenous) basal infusion rate.  
This system has been tested in VIVO (venous input venous output) on ten type-1 
diabetic hospitalized patients both in response to a 75g oral glucose load and to a 
standard meal. Three therapeutic regimens were employed:  
1 Regular insulin-injected SC,  
2 Lispro-injected SC,  
3 Regular insulin- injected IV.  
The obtained results using the IV regular insulin were similar to those achieved 
with the SC Lispro, with the only statistical difference being plasma insulin 
concentration values were higher in the SC case. On the other hand, the results 
obtained by injecting SC regular insulin were significantly worse than that by IV:  
(1) The total dose of insulin was significantly in SC is higher than IV, 
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(2) And plasma insulin concentrations were lower (30 min) and higher (90 – 300 
min), with consequent presence of hyperglycemic peaks followed by 
hypoglycemic episodes.  
The pole-assignment strategy proved to be not robust and requires an iterative 
assessment of the model parameters, which is difficult to have in clinical practice. 
2.3.5.  Optimal Control: 
The optimal control techniques implemented in diabetes treatment used linear 
diabetic patient model and a quadratic performance criterion (cost function), 
Swan (1982) [98] solved the glucose control problem for the optimal insulin 
infusion rate.  
                                𝐽𝐽1(𝑢𝑢) = ∫ [𝑥𝑥12∞0 (𝑡𝑡) + 𝜌𝜌𝑢𝑢2(𝑡𝑡)]𝑑𝑑𝑡𝑡                                  (2.32) 
This approach combine optimal control theory and solution of a nonlinear 
algebraic Riccati equation, and it refines the results of Kikuchi [56, 57], who 
solved the problem using an approximate solution to the Riccati equation. Kikuchi 
focused on the initially hyperglycemic diabetic patient and excluded meal 
disturbance attenuation. After that, Fisher and Teo [27] applied the optimal 
techniques to control patient blood glucose but they took into consideration both 
meal consumption and initial hyperglycemia. The performance measure used is: 
                                                    𝐽𝐽 = ∫ 𝑥𝑥12𝑇𝑇0  𝑑𝑑𝑡𝑡                                            (2.33) 
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where T = 240 min. 
The objective of optimal infusion protocols is to minimize the sum-squared of 
glucose tracking error. Impulse control (a single injection at time = 0 min) given 
by: 
                                 𝑢𝑢(𝑡𝑡) = �𝑢𝑢0 𝑡𝑡𝑏𝑏     � 𝑚𝑚𝑓𝑓  0 ≤ 𝑡𝑡 ≤ 𝑡𝑡𝑏𝑏 0     𝑚𝑚𝑓𝑓  𝑡𝑡 > 𝑡𝑡𝑏𝑏                                  (2.34) 
where 𝑡𝑡𝑏𝑏  is the time taken for the injection and 𝑢𝑢0 is the total amount of insulin injected. 
It showed superior control in both cases, with perfect reference tracking 
achievable if a good estimate of the meal was available under the assumption that 
the rate at which the glucose enters the blood 𝑝𝑝(𝑡𝑡) takes the following form: 
        𝑝𝑝(𝑡𝑡) = �          𝐵𝐵                                        𝑚𝑚𝑓𝑓 0 < 𝑡𝑡 < 𝑡𝑡𝑎𝑎
𝐵𝐵 exp�−𝛽𝛽(𝑡𝑡 − 𝑡𝑡𝑎𝑎)�      𝑚𝑚𝑓𝑓 𝑡𝑡 ≥ 𝑡𝑡𝑎𝑎                              (2.35) 
 Where 𝐵𝐵 , 𝛽𝛽, 𝑡𝑡𝑎𝑎  are constant. 
 However, this form was found not be practical one because this rate differ from 
patient to patient. To overcome this problem, Lim and Teo [65] added fuzzy 
model parameters enhancement to compensate for patient uncertainty. These 
techniques were tested for the chosen uncertainty set and it proved to be robust 
and numerically stable.  
Also, optimal control was applied by using the “minimal model” of Bergman, et 
al. [85, 86] in two studies. The first one was done by Ollerton [75], who utilized 
concept of an integral-squared error (ISE) cost function based on deviation from 
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the desired glucose value by using sampling times of 10 min and 180 min. 
Although the longer sampling time was less sensitive to noise about the basal 
state, Ollerton discretized the “minimal model” in 10 min sampling time because 
as the sampling time increases, the rise time also increases which might miss 
significant disturbance. This controller showed physiologically unrealistic profiles 
and high amplitude oscillation because it was sensitive to oscillation of the 
glucose profile about the basal state. 
An insensitive model was proposed to overcome sensitivity problem, most likely 
based on a type of dead-band control. Fisher [28] conducted another study by 
using the same “minimal model,” and an ISE-based objective function.  
                                                  𝐽𝐽(𝑢𝑢) = ∫ 𝑑𝑑2𝑇𝑇0 (𝑡𝑡)𝑑𝑑𝑡𝑡                                        (2.36) 
Subject to the constraint 
0 ≤ 𝑢𝑢(𝑡𝑡) ≤ 𝑢𝑢𝑚𝑚𝑎𝑎𝑥𝑥  for all 𝑡𝑡 ∈ [0,𝑇𝑇] 
His cost criterion had two objectives: 
 1)  Minimize deviations in glucose concentration from a reference value 
(Primary objective).  
2)  Minimize the amount of insulin used for the corrective action  
(Secondary objective).  
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The study tested three insulin infusion profiles, in which the cost function for an 
initially hyperglycemic patient was minimized by determining that an initial 
injection plus optimal hourly infusion. However, this algorithm was not robust to 
patient uncertainty, and because it has a long sampling time (180 min) it missed 
some important disturbances (fast or inter-sample disturbances). 
          2.2.6. Robust Control (𝑯𝑯∞) 
Robust control techniques with H∞ criteria was implemented by Kienitz an d 
Yoneyama [53] using a low-order model containing patient-dependent parameters 
on the following assumptions.  
(1) The main controller was constructed based on a nominal patient model,  
(2) Because of the variations between the patients (parameter variations), the 
set of frequency-dependent weighting functions was tuned to capture the 
entire expected patient population. So the controller managed the glucose 
level in the patient within this range of variation.  
This controller can sustain meal disturbance for the nominal patients which is a 
worthwhile improvement compared to the previous controllers. However, the 
controller is robust to a small range of variation and it requires to be retuned 
outside this range.  
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2.3.6.  Self-Tuning Adaptive Control: 
Glucose level in a diabetic person and its response to insulin depends on several 
factors such as insulin time sensitivity varies during the day, and the fitness and 
health of the individual. Because of that, adaptive control is an attractive 
technique to automate insulin delivery and to compensate for the patient variation 
and unknown conditions.  
 There are several papers published on using adaptive control for diabetes 
problem. In fact, most of the used adaptive techniques ware summarized in a 
review paper by Hovorka in 2004[91], for both type-1 and type-2 diabetes. He 
considers strategies for two types of situations:  
a. Infrequent glucose measurements are available (e.g., four to seven 
measurements per day).  
b. Frequent glucose measurements are available (e.g., every five 
minutes). 
The work of Shimoda  [97], is an important example of a successful use of the SC 
route for the closed loop control of insulin-dependent diabetic patients. The 
reason is mainly the use of Lispro insulin, which is better suited for SC closed-
loop control than regular insulin, since it behaves like IV-injected insulin. In fact, 
the strength of adaptive techniques is that it does not need to re-assess the patient 
parameters periodically, and so there is no need to retune controller parameters. 
These techniques were tested by several authors and showed good results 
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compared to standard techniques such as pole placement. The feasibility of these 
techniques was shown by Candas and Radziuk  [19], & Brunetti [17], in a closed-
loop system based on SC Lispro injections and SC measurements. The adaptive 
strategies which were based on a self-tuning minimum variance controller were 
conducted by Fisher [29], and improved by Brunetti & Fabietti [26]. This 
technique represents the glucose-insulin system by the following discrete-time 
model M: 
                            𝑑𝑑𝑘𝑘 = 𝑀𝑀(𝑑𝑑𝑘𝑘−1, … … ,𝑑𝑑𝑘𝑘−ℎ , 𝐼𝐼𝐷𝐷𝑘𝑘−𝑝𝑝 ,Θ)                                    (2.37) 
where: 
(1) Gk is blood glucose concentration at time k,  
(2)  IDk is insulin dose at time k,  
(3)  Θ is a set of unknown parameters, with h and p known time delays.  
The recursive techniques were used to estimate the parameter at each time k, on 
the basis of Gk measurement, which provide a prediction horizon of a one-step-
ahead, Gk+1, which can be utilized in the on-line regulator design. In fact, the 
choice of the next dose, IDk+1
                                          𝐽𝐽𝑘𝑘 = (𝑑𝑑𝑘𝑘+1 − 𝑑𝑑𝑏𝑏)2 − 𝑟𝑟𝐼𝐼𝐷𝐷𝑘𝑘+12                                 (2.38) 
, is done so as to minimize a suitable cost function, 
J, which in the case of a minimum variance controller is: 
where : 
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Gb
 
 is the set point. 
 r is a weighting factor that penalizes insulin dosage. 
thus compromising between the amount of infused insulin and 
hyper/hypoglycemia. One can assume, like in Fabietti [26], Candas [19] & 
Fisher[29], that M is linear, so that both the recursive estimation and the 
minimization problem can be solved in closed form. Given the adaptive capability 
of the algorithm, the choice of a linear model with time-varying parameters seems 
appropriate. 
 
 
 
2.3.7. Nonlinear Predictive Control: 
Nonlinear predictive control was proposed by Trajanoski et al. [76,99] to manage 
the glucose level in patients with the subcutaneous (SC) route. 
 The keys points of this technique are as follows: 
1. It performs several control actions that minimize a certain cost function 
within a selected time horizon.  
Figure 2.4: Self Tuning Adaptive control block diagram.[80] 
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2. This cost function does not depend on the control actions to predict the 
controlled variables but it utilizes an appropriate model for prediction.  
3. The control policy is refined by shifting the time window used for the cost 
function calculation at each sampling time.  
The methodology of this technique is similar to that used in adaptive control. 
However, there two main differences:  
 The selected model in adaptive techniques could be the same for the entire 
time window, and it does not require to be modified, unlike the one used 
in nonlinear techniques.  
 On the other hand, the control policy requires recalculation, since the 
optimization problem to be solved changes in accordance with the 
progressive shifts of the time window.  
In other words, instead of model parameter estimation of a nonlinear predictor in 
Fig. 4,the model used to predict future blood glucose levels is  nonlinear and 
autoregressive (NARX): 
𝑑𝑑𝑘𝑘 = 𝑓𝑓(𝑥𝑥𝑘𝑘) + 𝑒𝑒𝑘𝑘  = 𝑓𝑓(𝑑𝑑𝑘𝑘−1, … … . . ,𝑑𝑑𝑘𝑘−𝑛𝑛𝑦𝑦 , 𝐼𝐼𝐷𝐷𝑘𝑘−1,……,𝐼𝐼𝐷𝐷𝑘𝑘−𝑛𝑛𝑦𝑦 ,)                  (2.39) 
where  
Gk
 ID
 is blood glucose concentration at time k, 
k insulin dose at time k,  
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n y and nu are the maximum lags for Gk and IDk
                             𝑓𝑓�𝑥𝑥(𝑡𝑡)� = ∑ 𝑤𝑤𝑚𝑚𝐻𝐻(�𝑥𝑥 − 𝑥𝑥𝑚𝑚0�𝑛𝑛𝑚𝑚=1 )                                   (2.40) 
 , respectively 
𝑥𝑥𝑘𝑘 = [𝑑𝑑𝐾𝐾−1, … … ,𝑑𝑑𝐾𝐾−𝑛𝑛𝑦𝑦 , 𝐼𝐼𝐷𝐷𝑘𝑘−1, … . . , 𝐼𝐼𝐷𝐷𝑘𝑘−𝑛𝑛𝑢𝑢 ]𝑇𝑇  
The nonlinear function f can be selected by using the neural network technique, as 
follows  
where H is a continuous function from Rny+ nu
𝑥𝑥𝑚𝑚
0 are the n-centers of the RBFs.  
In [13], H was assumed as: 
 → R,  ‖ ‖ is the Euclidean norm,  
                      𝐻𝐻(�𝑥𝑥 − 𝑥𝑥𝑚𝑚0� = 1(�𝑥𝑥−𝑥𝑥𝑚𝑚0�2+𝛽𝛽 )2                                                (2.41) 
where β is a dispersion parameter. 
The control input (i.e., the SC insulin infusion rate) corresponds to the solution of 
the minimization problem:  
arg min𝐼𝐼𝐷𝐷 𝐽𝐽 =  ∑ [(𝑒𝑒𝑗𝑗𝑇𝑇Γ𝑒𝑒𝑗𝑗 )𝑁𝑁𝑃𝑃𝑗𝑗=𝑁𝑁1 + ∑ (Δ𝐼𝐼𝐷𝐷𝑇𝑇(𝑡𝑡 + 𝑗𝑗)ΓuΔ𝐼𝐼𝐷𝐷𝑇𝑇(𝑡𝑡 + 𝑗𝑗))] 𝑁𝑁𝑠𝑠−1𝑗𝑗=0       (2.42) 
𝐼𝐼𝐷𝐷 = [𝐼𝐼𝐷𝐷𝑘𝑘 , 𝐼𝐼𝐷𝐷𝑘𝑘−1, … … , 𝐼𝐼𝐷𝐷𝑘𝑘−𝑁𝑁𝑠𝑠−1]𝑇𝑇  
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Nc , N p, N1, Γe , Γu
2.4. Conclusion 
 are tuning parameters of the controller, selected by trial and 
error.  
The predictive control was tested and showed flexibility in managing blood 
glucose, even if there is disturbances and parameter variations (i.e., variations in 
the time constants of the system). In fact, the adoption of this proposed controller 
to treat diabetic patients is promising. 
However, under the presence of meals and lack of in-vivo validation hampers, the 
results were not good enough to adapt this technique to the patients. 
Several mathematical models were formulated to describe and mimic the actual process, 
in the glucose –insulin system in the human body. These models can be classified 
according to the mathematical form in which they are formulated. The main forms are: 
 
None of these models is able to fully describe the actual process and each of them has its 
advantages and weakness.  
Ordinary differential equation.
Integral differential equation.
Partial differential equation.
Delay differentila eqution.
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In this study, we select from the previous model, the time delay model type because: 
a. Using the time delay model is more realistic in physiology, because the 
glucose- insulin system has significant time delays which cannot be 
ignored.  
b. The two time delay model (2.17) has the two main significant time delays 
in the system which is required to describe the real situation correctly. 
Also, it conforms with physiological characteristics as shown both 
analytically and numerically  
Also, various control algorithms were used and tested to treat diabetes patients. Most of 
these control techniques are model-dependent, such as model predictive control. Some 
techniques are model-independent such as run-run control techniques. Optimal, robust 
and adaptive and run-run control, model independent type, are the most attractive 
techniques because they can sustain parameters variations, which is always the case in 
actual process. Moreover, they can handle meal disturbance which was one of main 
obstacles in earlier treatment trials.    
 In this study, we will use the LMI technique with 𝐻𝐻∞  criteria to stabilize the glucose-
insulin system. Also, we will develop a controller (with the same technique and criteria) 
which is stabilizing the plant (glucose-insulin system) and track a model with the desired 
performance characteristics at the same time.  
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CHAPTER 3 
 
TWO TIME DELAY MODEL 
 
3.1. Model Description 
 The selected DDE (delay differential equation) model has two explicit time delays and 
describes the glucose–insulin endocrine metabolic regulatory system. The reason for 
introducing these two time delays is that the in sulin  secretion b y β cell in  the liv er to  
manage glucose concentration in the bloodstream or the plasma takes about 5-15 minutes, 
depending on different individuals. So, to make the model more realistic and precise, 
these two delays must be introduced in the model. The two time delays are: 
(1) The effect of glucose concentration level on insulin secretion time delay τ1 due to the 
complex electro-chemical reactions when the rising glucose concentration level triggers 
the β cells to release insulin [52, 100, 50]. The delay τ1 can be described as insulin 
response time delay.  
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(2) The hepatic glucose production time delay τ2
𝑑𝑑𝑑𝑑 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑑𝑑𝑚𝑚𝑛𝑛 − 𝑓𝑓2�𝑑𝑑(𝑡𝑡)� − 𝑓𝑓3�𝑑𝑑(𝑡𝑡)�𝑓𝑓4�𝐼𝐼(𝑡𝑡)� + 𝑓𝑓5�𝐼𝐼(𝑡𝑡 − 𝜏𝜏2)�                                  (3.1) 
. In fact, this delay is introduced because 
the process of converting the stored glucose and glycogen into glucose and vice versa is 
done gradually and it takes some time.  
The two time delay DDE model selected is as follows: 
 𝑑𝑑𝐼𝐼(𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝑓𝑓1�𝑑𝑑(𝑡𝑡 − 𝜏𝜏1)� − 𝑑𝑑𝑚𝑚𝐼𝐼(𝑡𝑡) 
where the initial condition I(0) = I0 > 0, G(0) = G0 > 0,G(t) ≡ G0 for all t ∈ [−τ1, 0] 
and I(t) ≡ I0 for t ∈ [−τ2, 0] with τ1, τ2 > 0. 
where:  
f1(G) = Rm/(1+exp((C1-G/Vg)/a1)),                                                                               (3.2) 
f2(G) = Ub(1-exp(-G/(C2Vg))),                                                                                       
(3.3) 
f3(G) = G/(C3Vg);                                                                                                          (3.4) 
f4(I) = U0+(Um-U0)/(1+exp(-β ln(I/C4(1/Vi+1(Eti
f
)))))                                                  
(3.5) 
5(I) = Rg/(1+exp(α(I/Vp-C5)));                                                                                     (3.6) 
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1) Gin
2) f
 is due to glucose infusion, e.g., by meal ingestion, oral glucose intake, 
continuous enteral nutrition or intravenous glucose infusion; 
2
3) 𝑓𝑓2(0) = 0,𝑓𝑓2(𝑥𝑥) > 0 𝑎𝑎𝑛𝑛𝑑𝑑 𝑓𝑓2′(𝑥𝑥) > 0 𝑎𝑎𝑟𝑟𝑒𝑒 𝑏𝑏𝑜𝑜𝑢𝑢𝑛𝑛𝑑𝑑𝑒𝑒𝑑𝑑 𝑓𝑓𝑜𝑜𝑟𝑟 𝑥𝑥 > 0  , 𝑓𝑓3�𝑑𝑑(𝑡𝑡)�𝑓𝑓4(𝐼𝐼(𝑡𝑡) 
represents insulin dependent utilization/uptake by muscle, fat cells and others 
parts of the body. This utilization is accomplished by the so-called ‘‘remote 
insulin’’.   
(G(t)) stands for insulin independent glucose consumption by the brain, nerve 
cells and other parts of the body. So, this type of utilization depends on glucose 
concentration level only. 
f3(x) = k3x, where  k3 > 0 𝑚𝑚𝑠𝑠 𝑎𝑎 𝑠𝑠𝑜𝑜𝑛𝑛𝑠𝑠𝑡𝑡𝑎𝑎𝑛𝑛𝑡𝑡. f4(0) > 0  , for x > 0, f4(x) >0 𝑎𝑎𝑛𝑛𝑑𝑑 f4′ (x) > 0 𝑎𝑎𝑟𝑟𝑒𝑒 𝑏𝑏𝑜𝑜𝑢𝑢𝑛𝑛𝑑𝑑𝑒𝑒𝑑𝑑 𝑎𝑎𝑏𝑏𝑜𝑜𝑎𝑎𝑒𝑒. f4(I(t)) is in sigmodial. 
4) 𝑓𝑓5(𝐼𝐼(𝑡𝑡 − 𝜏𝜏2)) Indicates hepatic glucose production that is dependent on insulin in 
the plasma with time delay τ2 > 0. The time delay τ2
5) 𝑓𝑓1(𝐼𝐼(𝑡𝑡 − 𝜏𝜏1))  stands for insulin secretion from the pancreas. Insulin is stored in 
β-cell granules. Glucose is the primary stimulus of insulin secretion from β cells. 
The delay is due to the complex electric processes inside an islet. These processes 
include glucose molecules that enter islets through Glucose Transporter GLUT2, 
elevate ATP and then close the K+ channels. When K+ channels are closed, Ca2+ 
channels are open. 
 > 0 reflects that the. 𝑓𝑓5(0) >0 and,𝑓𝑓𝑜𝑜𝑟𝑟 𝑥𝑥 > 0,𝑓𝑓5(𝑥𝑥) > 0 and 𝑓𝑓5′(𝑥𝑥) < 0. 𝑓𝑓5(𝑥𝑥) and |𝑓𝑓5′(𝑥𝑥)| are bounded 
above for x > 0.    𝑓𝑓5(𝑥𝑥) is in an inverse sigmoidal shape. 
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6) 𝑑𝑑𝑚𝑚𝐼𝐼(𝑡𝑡) stands for insulin degradation and constant 𝑑𝑑𝑚𝑚  is the degradation rate. The 
liver and kidney respectively are the primary sites of portal insulin degradation 
and peripheral insulin clearance. The remaining Insulin which is not cleared by 
liver and kidney [32] is ultimately removed by other tissues such as muscle and 
adipose cells.  
 
Table 3.3: Function Parameters values 
Parameters Units Values Parameters Units Values 
𝑽𝑽𝒈𝒈 1 10 𝑈𝑈0 mg. min-1 40 
𝑹𝑹𝒃𝒃 𝜇𝜇Umin 210 
-1 𝑈𝑈𝑚𝑚  mg. min 940 
-1 
𝒂𝒂𝟏𝟏 mg.1
-1 300 𝛽𝛽  1.77 
𝑪𝑪𝟏𝟏 mg.1 2000 
-1 𝐶𝐶4 𝜇𝜇U1 80 -1 
𝑼𝑼𝒃𝒃 mg. min
-1 72 𝑅𝑅𝑚𝑚  mg. min
-1 180 
𝑪𝑪𝟐𝟐 mg.1 144 
-1 𝛼𝛼 𝑢𝑢𝜇𝜇U1 0.29 -1 
𝑪𝑪𝟑𝟑 mg.1
-1 1000 𝐶𝐶5 𝜇𝜇U1-1 26 
𝒖𝒖𝒑𝒑 min 6 E 1min 0.2 
-1 
𝒖𝒖𝒊𝒊 min 100 𝑡𝑡𝑑𝑑  min 36 
𝑽𝑽𝒑𝒑  1 3 𝑉𝑉𝑚𝑚  1 11 
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By using the same experimental data set which is used in the existing  mathematical 
models such as those in Sturis et al. and Tolic et al. [44,20] ,the two time delay model 
confirms most of existing observations of experiments and models, and it shows more 
robustness, and better agreement with physiological data. 
 
 
Figure 3.5:Functions Shapes. 
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Figure 3.6: Two Time Delay Glucose-Insulin Regulatory Model. [50] 
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3.2. Linear Model: 
The previous two time delay model is nonlinear. Therefore, we need to linearize the 
model to implement the proposed control strategies, so that it becomes easy to deal with 
and to analyze. 
let 𝑑𝑑(𝑡𝑡) = 𝑑𝑑1(𝑡𝑡) + 𝑑𝑑∗ and 𝐼𝐼(𝑡𝑡) = 𝐼𝐼1(𝑡𝑡) + 𝐼𝐼∗  and using Taylor series expansion  
𝑑𝑑1′ (𝑡𝑡) = 𝑑𝑑𝑚𝑚𝑛𝑛 − 𝑓𝑓2(𝑑𝑑1(𝑡𝑡) + 𝑑𝑑∗) − 𝑓𝑓3(𝑑𝑑1(𝑡𝑡) + 𝑑𝑑∗)𝑓𝑓4(𝐼𝐼1(𝑡𝑡) + 𝐼𝐼∗) + 𝑓𝑓5(𝐼𝐼1(𝑡𝑡 − 𝜏𝜏2) + 𝐼𝐼∗)  
        = 𝑑𝑑𝑚𝑚𝑛𝑛 −  𝑓𝑓2(𝑑𝑑∗) − 𝑑𝑑1(𝑡𝑡)𝑓𝑓2′(𝑑𝑑∗) − 𝑓𝑓3(𝑑𝑑∗)𝑓𝑓4(𝐼𝐼∗) − 𝑑𝑑1(𝑡𝑡)𝑓𝑓3′(𝑑𝑑∗)𝑓𝑓4(𝐼𝐼∗) −            𝐼𝐼1(𝑡𝑡)𝑓𝑓4′(𝐼𝐼∗)𝑓𝑓3(𝑑𝑑∗) + 𝑓𝑓5(𝐼𝐼∗) + 𝐼𝐼1(𝑡𝑡 − 𝜏𝜏2)𝑓𝑓5′(𝐼𝐼∗) + 𝐻𝐻𝐻𝐻𝑇𝑇                                                            
𝑑𝑑1′ (𝑡𝑡) = (𝑑𝑑𝑚𝑚𝑛𝑛 − 𝑓𝑓3(𝑑𝑑∗)𝑓𝑓4(𝐼𝐼∗) − +𝑓𝑓5(𝐼𝐼∗) −  𝑓𝑓2(𝑑𝑑∗)) − 𝑑𝑑1(𝑡𝑡)𝑓𝑓2′(𝑑𝑑∗)
−    𝑑𝑑1(𝑡𝑡)𝑓𝑓3′(𝑑𝑑∗)𝑓𝑓4(𝐼𝐼∗) − 𝐼𝐼1(𝑡𝑡)𝑓𝑓4′(𝐼𝐼∗)𝑓𝑓3(𝑑𝑑∗) + 𝐼𝐼1(𝑡𝑡 − 𝜏𝜏2)𝑓𝑓5′(𝐼𝐼∗) + 𝐻𝐻𝐻𝐻𝑇𝑇 
   𝐼𝐼1′ (𝑡𝑡) = 𝑓𝑓1(𝑑𝑑1(𝑡𝑡 − 𝜏𝜏1) + 𝑑𝑑∗) − 𝑑𝑑𝑚𝑚(𝐼𝐼1(𝑡𝑡) + 𝐼𝐼∗)  
= 𝑓𝑓1(𝑑𝑑∗) + 𝑓𝑓1′(𝑑𝑑∗)𝑑𝑑1(𝑡𝑡 − 𝜏𝜏1) − 𝑑𝑑𝑚𝑚(𝐼𝐼1(𝑡𝑡) + 𝐼𝐼∗) + 𝐻𝐻𝐻𝐻𝑇𝑇  
So, after solving these two equations and ignoring the higher order term, the linear model 
will be as follows: 
   𝑑𝑑1′ (𝑡𝑡)  = −[𝑓𝑓2′(𝑑𝑑∗) + 𝑓𝑓3′(𝑑𝑑∗)𝑓𝑓4(𝐼𝐼∗)]𝑑𝑑1(𝑡𝑡) − 𝑓𝑓3(𝑑𝑑∗)𝑓𝑓4′(𝐼𝐼∗)𝐼𝐼1(𝑡𝑡) + 𝑓𝑓5′ (𝐼𝐼∗)𝐼𝐼1(𝑡𝑡 − 𝜏𝜏2)  
    𝐼𝐼1′ (𝑡𝑡)  = 𝑓𝑓1′(𝑑𝑑∗)𝑑𝑑1(𝑡𝑡 − 𝜏𝜏1) − 𝑑𝑑𝑚𝑚𝐼𝐼1(𝑡𝑡)                                                                     (3.7)                                              
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So, we can write the system in the following form: 
𝑑𝑑𝑑𝑑
𝑑𝑑𝑡𝑡
= −𝐴𝐴𝑑𝑑(𝑡𝑡) − 𝐵𝐵𝐼𝐼(𝑡𝑡) − 𝐶𝐶𝐼𝐼(𝑡𝑡 − 𝜏𝜏2) 
                                                𝑑𝑑𝐼𝐼 (𝑡𝑡)
𝑑𝑑𝑡𝑡
= 𝐷𝐷𝑑𝑑(𝑡𝑡 − 𝜏𝜏1) − 𝑑𝑑𝑚𝑚𝐼𝐼(𝑡𝑡)                                          (3.8) 
where:  
𝐴𝐴 = 𝑓𝑓2′ (𝑑𝑑∗) + 𝑓𝑓3′ (𝑑𝑑∗)𝑓𝑓4(𝐼𝐼∗) > 0. 
B = 𝑓𝑓3(𝑑𝑑∗)𝑓𝑓4′(𝐼𝐼∗) > 0 . 
𝐶𝐶 = −𝑓𝑓5′ (𝐼𝐼∗) > 0. 
𝐷𝐷 = 𝑓𝑓1′(𝑑𝑑∗) > 0 
The Standard Linear Time Delay System: 
?̇?𝑥(𝑡𝑡) = 𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴𝑑𝑑1𝑥𝑥(𝑡𝑡 − 𝜏𝜏1) + 𝐴𝐴𝑑𝑑2𝑥𝑥(𝑡𝑡 − 𝜏𝜏2) + Ε𝑢𝑢(𝑡𝑡) + Γ𝑤𝑤 
𝑦𝑦(𝑡𝑡) = 𝐶𝐶𝑥𝑥(𝑡𝑡) + 𝐷𝐷𝑢𝑢(𝑡𝑡) 
where: 
𝐴𝐴 = �−𝐴𝐴 −𝐵𝐵0 −𝐶𝐶�  ; 
𝐴𝐴𝑑𝑑1 = �0 0𝐷𝐷 0� ; 
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𝐴𝐴𝑑𝑑2 = �0 −𝐶𝐶0 0 � ; 
Two methods are used to control the glucose- insulin regulatory system: 
1) Controlling the system by using both insulin and glucose to keep the balance in 
the patient. However, this technique failed. 
2) Controlling the system by using insulin dosage only while the glucose can be 
taken as carbohydrate by the patient. So, our goal is to deal only with 
hyperglycemia, in which the glucose level is above 140 mg/dl, and to reduce the 
glucose to Normoglycemia level (70-110 mg/dl). So, we have only one control 
input, and the input weight matrix will be as follows: 
𝐸𝐸 = �01� ; 
So, if we linearized the model around the operating point (9500, 90), the system matrices: 
𝐴𝐴 = �−0.0902 −0.69460 −0.0600� 
𝐴𝐴𝑑𝑑1 = � 0 00.0012 0� 
𝐴𝐴𝑑𝑑2 = �0 −3.75940 0 � 
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CHAPTER 4 
 
SOLUTION VIA LINEAR MATRIX INEQUALITY (LMI) 
 
4.1. Introduction 
 
Linear Matrix Inequality (LMI) is a useful and powerful design tool in control 
engineering system identification areas because of the following factors: 
1. A variety of design specifications and constraints can be expressed as LMIs. 
2. Existence of efficient LMI solvers (using convex optimization algorithms). 
3. Unlike the analytical techniques, multiple constraints or objectives can be often 
traced by using LMI techniques.   
LMI techniques can be used also with a class of linear or nonlinear time delay systems 
for stability or control design. This chapter presents the LMI development for a linear 
system with two time delays (unknown constant – bounded type) based on 𝐻𝐻∞  criteria for 
the following: 
(1) Stability analysis. 
(2) State feedback. 
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(3) Tracking. 
4.2. Stability Analysis: 
 
Consider the following plant with single time delay: 
?̇?𝑥(𝑡𝑡) = 𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ𝑥𝑥(𝑡𝑡 − 𝜏𝜏) + 𝐵𝐵𝑢𝑢(𝑡𝑡) + 𝛤𝛤𝑜𝑜𝑤𝑤(𝑡𝑡)  
𝑦𝑦(𝑡𝑡) = 𝐶𝐶𝑥𝑥(𝑡𝑡) + 𝐷𝐷𝑢𝑢(𝑡𝑡) + 𝜓𝜓𝑜𝑜𝑤𝑤(𝑡𝑡)                                                    (4.1) 
𝑧𝑧(𝑡𝑡) = 𝑑𝑑𝑜𝑜𝑥𝑥(𝑡𝑡) + 𝑑𝑑𝑑𝑑𝑜𝑜𝑥𝑥(𝑡𝑡 − 𝜏𝜏) + 𝐷𝐷𝑜𝑜𝑢𝑢(𝑡𝑡) + 𝛷𝛷𝑜𝑜𝑤𝑤(𝑡𝑡). 
where 𝑥𝑥(𝑡𝑡) ∈ ℝ𝑛𝑛  is the state vector, 𝑢𝑢(𝑡𝑡) ∈ ℝ𝑚𝑚  is the control input , 𝑤𝑤(𝑡𝑡) ∈ ℝ𝑞𝑞  is the 
disturbance input &   𝑧𝑧(𝑡𝑡) ∈ ℝ𝑡𝑡  is the controlled output and 𝜏𝜏 is a constant time delay. 
Theorem: 
The above plant will be stable if for 0 < 𝑃𝑃 = 𝑃𝑃𝑡𝑡 , 0 < 𝑊𝑊 = 𝑊𝑊𝑡𝑡 , 0 < 𝑄𝑄 = 𝑄𝑄𝑡𝑡 , the 
following LMI is satisfied: 
𝛯𝛯 =
⎣
⎢
⎢
⎢
⎢
⎡𝛯𝛯11
•
•
•
•
•
    
𝛯𝛯12
𝛯𝛯22
•
•
•
•
    
𝜏𝜏𝜏𝜏
−𝜏𝜏𝜏𝜏
−𝜏𝜏𝑊𝑊
•
•
•
     
𝑃𝑃𝛤𝛤𝑜𝑜00
−𝛾𝛾2𝐼𝐼
•
•
    
𝑑𝑑𝑜𝑜
𝑡𝑡
𝑑𝑑𝑑𝑑𝑜𝑜
𝑡𝑡0
𝛷𝛷𝑜𝑜
𝑡𝑡
−𝐼𝐼
•
    
−𝜏𝜏𝐴𝐴𝑡𝑡𝑊𝑊
−𝜏𝜏𝐴𝐴ℎ
𝑡𝑡𝑊𝑊0
−𝜏𝜏𝛤𝛤𝑜𝑜
𝑡𝑡𝑊𝑊0
−𝜏𝜏𝑊𝑊 ⎦
⎥
⎥
⎥
⎥
⎤ < 0                                           (4.2) 
where  
𝜏𝜏 ∈ ℜ𝑛𝑛×𝑛𝑛 , and 𝜏𝜏 ∈ ℜ𝑛𝑛×𝑛𝑛    are appropriate relaxation matrices. 
𝑄𝑄 & 𝑊𝑊 are weighting matrices. 
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𝛯𝛯11 = 𝑃𝑃𝐴𝐴 + 𝐴𝐴𝑡𝑡𝑃𝑃 + 𝜏𝜏 + 𝜏𝜏𝑡𝑡 + 𝑄𝑄 
𝛯𝛯12 = 𝑃𝑃𝐴𝐴ℎ − 𝜏𝜏 + 𝜏𝜏𝑡𝑡  
𝛯𝛯22 = −𝜏𝜏 − 𝜏𝜏𝑡𝑡 − 𝑄𝑄 
Proof: 
Consider the Lyapunov-Krasovskii Function: 
𝑉𝑉(𝑡𝑡) = 𝑉𝑉𝑜𝑜 (𝑡𝑡) + 𝑉𝑉𝑎𝑎(𝑡𝑡) + 𝑉𝑉𝑚𝑚 (𝑡𝑡)                                                                                      (4.3) 
𝑉𝑉𝑜𝑜(𝑡𝑡) = 𝑥𝑥𝑡𝑡(𝑡𝑡)𝛲𝛲𝑥𝑥(𝑡𝑡)                                                                                                       (4.4) 
𝑉𝑉𝑎𝑎 (𝑡𝑡) = ∫ ∫ ?̇?𝑥𝑡𝑡(𝛼𝛼)𝑊𝑊?̇?𝑥𝑡𝑡𝑡𝑡+𝑠𝑠0−𝜏𝜏 (𝛼𝛼)𝑑𝑑𝛼𝛼𝑑𝑑𝑠𝑠                                                                              (4.5) 
𝑉𝑉𝑚𝑚 (𝑡𝑡) = ∫ 𝑥𝑥𝑡𝑡(𝑠𝑠)𝑄𝑄𝑥𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠                                                                                          (4.6) 
The first term is the standard to the delayless nominal system, and the second and the 
third terms correspond to the delay-dependent condition. 
?̇?𝑉(𝑡𝑡) = 𝑉𝑉?̇?𝑜 (𝑡𝑡) + 𝑉𝑉?̇?𝑎(𝑡𝑡) + 𝑉𝑉?̇?𝑚 (𝑡𝑡)                                                                                   (4.7)               
𝑉𝑉?̇?𝑜(𝑡𝑡) = ?̇?𝑥𝑡𝑡(𝑡𝑡)𝛲𝛲𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡)𝛲𝛲?̇?𝑥(𝑡𝑡) = 2𝑥𝑥𝑡𝑡(𝑡𝑡)𝛲𝛲?̇?𝑥(𝑡𝑡)                                          
  𝑉𝑉?̇?𝑜(𝑡𝑡) = 2𝑥𝑥𝑡𝑡(𝑡𝑡)𝛲𝛲(𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ𝑥𝑥(𝑡𝑡 − 𝜏𝜏))  
 =2𝑥𝑥𝑡𝑡(𝑡𝑡)𝛲𝛲(𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ𝑥𝑥(𝑡𝑡 − 𝜏𝜏))                                                                                 (4.8)                                                                                           
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= 2𝑥𝑥𝑡𝑡(𝑡𝑡)𝑃𝑃[𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ𝑥𝑥(𝑡𝑡 − 𝜏𝜏)] + 2𝑥𝑥𝑡𝑡(𝑡𝑡)𝜏𝜏∫ ?̇?𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠 + 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏)𝜏𝜏∫ ?̇?𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠 −
�2𝑥𝑥𝑡𝑡(𝑡𝑡) 𝜏𝜏 ∫ ?̇?𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠 + 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏) 𝜏𝜏 ∫ ?̇?𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠�                             
= 2𝑥𝑥𝑡𝑡(𝑡𝑡)𝑃𝑃[𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ𝑥𝑥(𝑡𝑡 − 𝜏𝜏)] + 2𝑥𝑥𝑡𝑡(𝑡𝑡)𝜏𝜏[𝑥𝑥(𝑡𝑡) − 𝑥𝑥(𝑡𝑡 − 𝜏𝜏)] + 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏)𝜏𝜏[𝑥𝑥(𝑡𝑡) − 𝑥𝑥(𝑡𝑡 − 𝜏𝜏)] − �2𝑥𝑥𝑡𝑡(𝑡𝑡) 𝜏𝜏 ∫ ?̇?𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠 + 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏)  𝜏𝜏 ∫  ?̇?𝑥(𝑠𝑠) 𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠�                               
= 2𝑥𝑥𝑡𝑡(𝑡𝑡)[𝑃𝑃𝐴𝐴 + 𝜏𝜏]𝑥𝑥(𝑡𝑡) + 2𝑥𝑥𝑡𝑡(𝑡𝑡)[𝑃𝑃𝐴𝐴ℎ − 𝜏𝜏 + 𝜏𝜏𝑡𝑡]𝑥𝑥(𝑡𝑡 − 𝜏𝜏) + 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏)(−𝜏𝜏)𝑥𝑥(𝑡𝑡 − 𝜏𝜏) −2𝑥𝑥𝑡𝑡(𝑡𝑡) 𝜏𝜏  ∫ ?̇?𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠 − 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏) 𝜏𝜏 ∫ ?̇?𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠  
= 𝑥𝑥𝑡𝑡(𝑡𝑡)𝑃𝑃𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡)𝐴𝐴𝑡𝑡𝑃𝑃𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡)𝜏𝜏𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡)𝜏𝜏𝑡𝑡𝑥𝑥(𝑡𝑡) + 2𝑥𝑥𝑡𝑡(𝑡𝑡)[𝑃𝑃𝐴𝐴ℎ − 𝜏𝜏 +
𝜏𝜏𝑡𝑡] 𝑥𝑥(𝑡𝑡 − 𝜏𝜏) + 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏) (−𝜏𝜏) 𝑥𝑥(𝑡𝑡 − 𝜏𝜏) − 2𝑥𝑥𝑡𝑡(𝑡𝑡) 𝜏𝜏 ∫ ?̇?𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠 − 2𝑥𝑥𝑡𝑡(𝑡𝑡 −
𝜏𝜏) 𝜏𝜏 ∫ ?̇?𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠  
1
𝜏𝜏
∫ [𝑥𝑥𝑡𝑡(𝑡𝑡)𝑃𝑃𝐴𝐴 𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡)𝐴𝐴𝑡𝑡𝑃𝑃𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡)𝜏𝜏𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡)𝜏𝜏𝑡𝑡𝑥𝑥(𝑡𝑡) + 2𝑥𝑥𝑡𝑡(𝑡𝑡)[𝑃𝑃𝐴𝐴ℎ − 𝜏𝜏 +𝑡𝑡𝑡𝑡−𝜏𝜏
𝜏𝜏𝑡𝑡]  𝑥𝑥(𝑡𝑡 − 𝜏𝜏) + 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏) (−𝜏𝜏) 𝑥𝑥(𝑡𝑡 − 𝜏𝜏) − 2𝑥𝑥𝑡𝑡(𝑡𝑡) 𝜏𝜏 𝜏𝜏 𝑥𝑥 ̇ (𝑠𝑠) − 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏) 𝜏𝜏 𝜏𝜏 ?̇?𝑥(𝑠𝑠)]𝑑𝑑𝑠𝑠           
(4.9) 
Where, 𝜏𝜏 ∈ ℜ𝑛𝑛×𝑛𝑛 , and 𝜏𝜏 ∈ ℜ𝑛𝑛×𝑛𝑛   are appropriate relaxation parameter matrices injected 
to facilitate the delay dependence analysis 
𝑉𝑉𝑎𝑎 (𝑡𝑡) = ∫ ∫ ?̇?𝑥𝑡𝑡(𝛼𝛼)𝑊𝑊?̇?𝑥𝑡𝑡𝑡𝑡+𝑠𝑠0−𝜏𝜏 (𝛼𝛼)𝑑𝑑𝛼𝛼𝑑𝑑𝑠𝑠                                                                       (4.10)                       
The Lybanze Rule yields: 
𝑉𝑉?̇?𝑎 (𝑡𝑡) = ∫ 𝑑𝑑𝑑𝑑𝑡𝑡 �∫ ?̇?𝑥𝑡𝑡(𝛼𝛼)𝑊𝑊?̇?𝑥(𝛼𝛼)𝑑𝑑𝛼𝛼𝑡𝑡𝑡𝑡+𝑠𝑠 � 𝑑𝑑𝑠𝑠0−𝜏𝜏   
63 
 
 
 
 = ��0 + ?̇?𝑥𝑡𝑡(𝑡𝑡)𝑊𝑊?̇?𝑥(𝑡𝑡) − ?̇?𝑥𝑡𝑡(𝑡𝑡 + 𝑠𝑠)𝑊𝑊?̇?𝑥(𝑡𝑡 + 𝑠𝑠)�𝑑𝑑𝑠𝑠0
−𝜏𝜏
 
= �[?̇?𝑥𝑡𝑡(𝑡𝑡)𝑊𝑊?̇?𝑥(𝑡𝑡) − �?̇?𝑥𝑡𝑡(𝑡𝑡 + 𝑠𝑠)𝑊𝑊?̇?𝑥(𝑡𝑡 + 𝑠𝑠)�]𝑑𝑑𝑠𝑠0
−𝜏𝜏
 
𝑡𝑡 + 𝑠𝑠 = 𝛼𝛼  , then = 𝑑𝑑𝛼𝛼 , when 𝑠𝑠 = −𝜏𝜏 then 𝛼𝛼 = 𝑡𝑡 − 𝜏𝜏, and when 𝑠𝑠 = 0 then 𝛼𝛼 = 𝑡𝑡 
thus: 
= ∫ [(?̇?𝑥𝑡𝑡(𝑡𝑡)𝑊𝑊?̇?𝑥(𝑡𝑡)) − (?̇?𝑥𝑡𝑡(𝑠𝑠)𝑊𝑊?̇?𝑥(𝑠𝑠))]𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠 
For the third function: 
𝑉𝑉?̇?𝑚 (𝑡𝑡) = 1𝜏𝜏 ∫ [𝑥𝑥𝑡𝑡(𝑡𝑡)𝑄𝑄𝑥𝑥(𝑡𝑡) − 𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏)𝑄𝑄𝑥𝑥(𝑡𝑡 − 𝜏𝜏)]𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠                                          (4.10)                                         
So, defining the state vector: 
𝜒𝜒(𝑡𝑡, 𝑠𝑠) = [𝑥𝑥𝑡𝑡(𝑡𝑡)   𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏)   ?̇?𝑥𝑡𝑡(𝑠𝑠) ]𝑡𝑡  
?̇?𝑉(𝑡𝑡) ≤ (𝜒𝜒𝑡𝑡(𝑡𝑡, 𝑠𝑠)𝛯𝛯ℎ𝜒𝜒(𝑡𝑡, 𝑠𝑠) + (?̇?𝑥𝑡𝑡(𝑡𝑡)𝑊𝑊?̇?𝑥(𝑡𝑡))  < 0 
where  
𝛯𝛯ℎ = �𝑃𝑃𝐴𝐴 + 𝐴𝐴𝑡𝑡𝑃𝑃 + 𝜏𝜏 + 𝜏𝜏𝑡𝑡 + 𝑄𝑄•
•
      𝑃𝑃𝐴𝐴ℎ − 𝜏𝜏 + 𝜏𝜏𝑡𝑡−𝜏𝜏 − 𝜏𝜏𝑡𝑡 − 𝑄𝑄
•
      𝜏𝜏𝜏𝜏−𝜏𝜏𝜏𝜏
−𝜏𝜏𝑊𝑊
      �  
Next we use the term  (𝑥𝑥̇ 𝑡𝑡(𝑡𝑡)𝑊𝑊?̇?𝑥(𝑡𝑡)) in 
?̇?𝑥(𝑡𝑡)  = 𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ𝑥𝑥(𝑡𝑡 − 𝜏𝜏) 
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Algebraic manipulation yields: 
𝜏𝜏?̇?𝑥𝑡𝑡(𝑡𝑡)𝑊𝑊?̇?𝑥(𝑡𝑡)= 𝜏𝜏𝜒𝜒𝑡𝑡?̅?𝐴𝑡𝑡𝑊𝑊?̅?𝐴𝜒𝜒 
?̇?𝑥(𝑡𝑡) = [𝐴𝐴     𝐴𝐴ℎ      0 ] � 𝑥𝑥(𝑡𝑡)𝑥𝑥(𝑡𝑡 − 𝜏𝜏)
?̇?𝑥(𝑠𝑠) �   
         = ?̅?𝐴𝜒𝜒(𝑡𝑡, 𝑠𝑠) ≜ ?̅?𝐴𝜒𝜒 
Therefore: 
?̇?𝑉(𝑡𝑡) = 𝜒𝜒𝑡𝑡𝛯𝛯ℎ𝜒𝜒 + 𝜏𝜏𝜒𝜒𝑡𝑡?̅?𝐴𝑡𝑡𝑊𝑊?̅?𝐴𝜒𝜒 
= 𝜒𝜒𝑡𝑡[𝛯𝛯ℎ + 𝜏𝜏?̅?𝐴𝑡𝑡𝑊𝑊?̅?𝐴]𝜒𝜒 
= 𝜒𝜒𝑡𝑡[𝛯𝛯ℎ + 𝜏𝜏?̅?𝐴𝑡𝑡𝑊𝑊𝑊𝑊−1𝑊𝑊?̅?𝐴]𝜒𝜒 
= 𝜒𝜒𝑡𝑡[𝛯𝛯ℎ + 𝜏𝜏?̅?𝐴𝑡𝑡𝑊𝑊𝜏𝜏−1𝑊𝑊−1𝑊𝑊?̅?𝐴𝜏𝜏]𝜒𝜒 < 0                                  (4.12)                                                       
By using the Schur complement , if 𝛯𝛯 < 0  then   
?̇?𝑉(𝑡𝑡) < 0         ⟹  the system is internally stable. 
Considering the following performance measure: 
𝐽𝐽 = ∫ �𝑧𝑧𝑡𝑡(𝑠𝑠)𝑧𝑧(𝑠𝑠) − 𝛾𝛾2𝑤𝑤𝑡𝑡(𝑠𝑠)𝑤𝑤(𝑠𝑠)�𝑑𝑑𝑠𝑠∞0                                             (4.13) 
For any 𝑤𝑤(𝑡𝑡) ∈ ℒ2 [0,∞) ≠ 0 and zero initial condition 𝑥𝑥(𝑡𝑡) = 0, then we can rewrite 
the performance measure as follows: 
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𝐽𝐽 = � �𝑧𝑧𝑡𝑡(𝑠𝑠)𝑧𝑧(𝑠𝑠) − 𝛾𝛾2𝑤𝑤𝑡𝑡(𝑠𝑠)𝑤𝑤(𝑠𝑠) + ?̇?𝑉(𝑠𝑠) − ?̇?𝑉(𝑠𝑠)�𝑑𝑑𝑠𝑠∞0
≤ � �𝑧𝑧𝑡𝑡(𝑠𝑠)𝑧𝑧(𝑠𝑠) − 𝛾𝛾2𝑤𝑤𝑡𝑡(𝑠𝑠)𝑤𝑤(𝑠𝑠) + ?̇?𝑉(𝑠𝑠)�𝑑𝑑𝑠𝑠∞0  
 
Let      ?̅?𝜒(𝑡𝑡, 𝑠𝑠) = [𝑥𝑥𝑡𝑡(𝑡𝑡)   𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏)   ?̇?𝑥𝑡𝑡(𝑠𝑠)  𝑤𝑤𝑡𝑡(𝑡𝑡)]𝑡𝑡  
Then, following the same development as before, and by using the Schur complement, it 
is clear that 
𝑧𝑧𝑡𝑡(𝑠𝑠)𝑧𝑧(𝑠𝑠) − 𝛾𝛾2𝑤𝑤𝑡𝑡(𝑠𝑠)𝑤𝑤(𝑠𝑠) + ?̇?𝑉(𝑥𝑥) = ?̅?𝜒𝑡𝑡(𝑡𝑡, 𝑠𝑠)𝛯𝛯�?̅?𝜒(𝑡𝑡, 𝑠𝑠) < 0 
for any arbitrary  𝑠𝑠 ∈ [t,∞), which implies for any 𝑤𝑤(𝑡𝑡) ∈ ℒ2 [0,∞) ≠ 0 that 𝐽𝐽 < 0 
leading to ‖𝑧𝑧(𝑡𝑡)‖2 < 𝛾𝛾‖𝑤𝑤(𝑡𝑡)‖2 
By using the Schur complement, and by including the performance measure J, the LMI 
(4.2) will be obtained. 
4.3. State Feedback Derivation: 
 
Applying the state-feedback control 𝑢𝑢(𝑡𝑡) = 𝐾𝐾𝑥𝑥(𝑡𝑡)  𝐴𝐴𝑠𝑠  = 𝐴𝐴 + 𝐵𝐵𝐾𝐾. It then follows from 
the previous analysis that the resulting closed-loop system is delay-independent and 
asymptotically stable with ℒ2 performance bound if there exist weighting matrices 𝑀𝑀; 𝑄𝑄; 
and parameter matrices 𝜏𝜏; 𝜏𝜏 and scalar  𝛾𝛾 > 0 satisfying the following LMI: 
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𝛯𝛯𝑠𝑠3 =
⎣
⎢
⎢
⎢
⎢
⎡𝛯𝛯𝑠𝑠311
•
•
•
•
•
    
𝛯𝛯𝑠𝑠312
𝛯𝛯𝑠𝑠322
•
•
•
•
    
𝜏𝜏𝜏𝜏1
−𝜏𝜏𝜏𝜏1
−𝜏𝜏𝜀𝜀𝑀𝑀
•
•
•
     
𝑀𝑀𝛤𝛤𝑜𝑜00
−𝛾𝛾2𝐼𝐼
•
•
    
𝑀𝑀𝑑𝑑𝑜𝑜
𝑡𝑡
𝑀𝑀𝑑𝑑𝑑𝑑𝑜𝑜
𝑡𝑡0
𝛷𝛷𝑜𝑜
𝑡𝑡
−𝐼𝐼
•
    
−𝜏𝜏𝑀𝑀𝐴𝐴𝑡𝑡
−𝜏𝜏𝑀𝑀𝐴𝐴ℎ
𝑡𝑡0
−𝜏𝜏𝛤𝛤𝑜𝑜
𝑡𝑡0
−𝜏𝜏𝜀𝜀−1𝑀𝑀⎦⎥
⎥
⎥
⎥
⎤ < 0                              (4.14) 
where: 
𝛯𝛯𝑠𝑠311 = 𝐴𝐴𝑠𝑠𝑀𝑀 + 𝑀𝑀𝐴𝐴𝑠𝑠𝑡𝑡 + 𝜏𝜏1 + 𝜏𝜏1𝑡𝑡 + 𝑄𝑄1= 𝐴𝐴𝑀𝑀 + 𝐵𝐵𝐵𝐵 + 𝑀𝑀𝐴𝐴𝑡𝑡 + 𝐵𝐵𝑡𝑡𝐵𝐵𝑡𝑡 + 𝜏𝜏1 + 𝜏𝜏1𝑡𝑡 + 𝑄𝑄1 
𝛯𝛯𝑠𝑠312 = 𝐴𝐴𝑑𝑑𝑜𝑜𝑀𝑀 − 𝜏𝜏1 + 𝜏𝜏1𝑡𝑡  
𝛯𝛯𝑠𝑠322 = −𝜏𝜏1 − 𝜏𝜏1𝑡𝑡 − 𝑄𝑄1 
Proof: 
From LMI (4.2) and replacing A by Ac=A+BK, the following LMI is obtained: 
𝛯𝛯𝐶𝐶 =
⎣
⎢
⎢
⎢
⎢
⎡𝛯𝛯𝑠𝑠11
•
•
•
•
•
    
𝛯𝛯𝑠𝑠12
𝛯𝛯𝑠𝑠22
•
•
•
•
    
𝜏𝜏𝜏𝜏
−𝜏𝜏𝜏𝜏
−𝜏𝜏𝑊𝑊
•
•
•
     
𝑃𝑃𝛤𝛤𝑜𝑜00
−𝛾𝛾2𝐼𝐼
•
•
    
𝑑𝑑𝑜𝑜
𝑡𝑡
𝑑𝑑𝑑𝑑𝑜𝑜
𝑡𝑡0
𝛷𝛷𝑜𝑜
𝑡𝑡
−𝐼𝐼
•
    
−𝜏𝜏𝐴𝐴𝑡𝑡𝑊𝑊
−𝜏𝜏𝐴𝐴ℎ
𝑡𝑡𝑊𝑊0
−𝜏𝜏𝛤𝛤𝑜𝑜
𝑡𝑡𝑊𝑊0
−𝜏𝜏𝑊𝑊 ⎦
⎥
⎥
⎥
⎥
⎤ < 0                                         
where 
𝛯𝛯𝑠𝑠11 = 𝑃𝑃𝐴𝐴𝑠𝑠 + 𝐴𝐴𝑠𝑠𝑡𝑡𝑃𝑃 + 𝜏𝜏 + 𝜏𝜏𝑡𝑡 + 𝑄𝑄 
𝛯𝛯𝑠𝑠12 = 𝛯𝛯12 = 𝑃𝑃𝐴𝐴𝑑𝑑𝑜𝑜 − 𝜏𝜏 + 𝜏𝜏𝑡𝑡  
𝛯𝛯𝑠𝑠22 = 𝛯𝛯22 = −𝜏𝜏 − 𝜏𝜏𝑡𝑡 − 𝑄𝑄 
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So, to develop the closed loop LMI , we do the following steps: 
1 We have to rewrite the LMI 𝛯𝛯 so that: 
𝛯𝛯𝐶𝐶1 = [𝐼𝐼   𝐼𝐼   𝐼𝐼   𝐼𝐼   𝐼𝐼   𝑊𝑊−1]𝛯𝛯𝐶𝐶[𝐼𝐼   𝐼𝐼   𝐼𝐼   𝐼𝐼   𝐼𝐼    𝑊𝑊−1]𝑡𝑡  
𝛯𝛯𝐶𝐶1 =
⎣
⎢
⎢
⎢
⎢
⎡𝛯𝛯𝑠𝑠11
•
•
•
•
•
    
𝛯𝛯𝑠𝑠12
𝛯𝛯𝑠𝑠22
•
•
•
•
    
𝜏𝜏𝜏𝜏
−𝜏𝜏𝜏𝜏
−𝜏𝜏𝑊𝑊
•
•
•
     
𝑃𝑃𝛤𝛤𝑜𝑜00
−𝛾𝛾2𝐼𝐼
•
•
    
𝑑𝑑𝑜𝑜
𝑡𝑡
𝑑𝑑𝑑𝑑𝑜𝑜
𝑡𝑡0
𝛷𝛷𝑜𝑜
𝑡𝑡
−𝐼𝐼
•
    
−𝜏𝜏𝐴𝐴𝑡𝑡
−𝜏𝜏𝐴𝐴ℎ
𝑡𝑡0
−𝜏𝜏𝛤𝛤𝑜𝑜
𝑡𝑡0
−𝜏𝜏𝑊𝑊−1⎦⎥
⎥
⎥
⎥
⎤ < 0                      (4.14) 
2 Multiply the new LMI 𝛯𝛯1 by the following terms: 
𝛯𝛯𝐶𝐶2 = [𝑀𝑀   𝑀𝑀   𝑀𝑀   𝐼𝐼   𝐼𝐼   𝐼𝐼]𝛯𝛯𝐶𝐶1[𝑀𝑀   𝑀𝑀   𝑀𝑀   𝐼𝐼   𝐼𝐼   𝐼𝐼]𝑡𝑡  
and substitute 𝑃𝑃 = 𝑀𝑀−1 
𝛯𝛯𝑠𝑠2 =
⎣
⎢
⎢
⎢
⎢
⎡𝑀𝑀𝛯𝛯𝑠𝑠11𝑀𝑀
•
•
•
•
•
    
𝑀𝑀𝛯𝛯𝑠𝑠12𝑀𝑀
𝑀𝑀𝛯𝛯𝑠𝑠22𝑀𝑀
•
•
•
•
    
𝜏𝜏𝑀𝑀𝜏𝜏𝑀𝑀
−𝜏𝜏𝑀𝑀𝜏𝜏𝑀𝑀
−𝜏𝜏𝑀𝑀𝑊𝑊𝑀𝑀
•
•
•
     
𝑀𝑀𝛤𝛤𝑜𝑜00
−𝛾𝛾2𝐼𝐼
•
•
    
𝑀𝑀𝑑𝑑𝑜𝑜
𝑡𝑡
𝑀𝑀𝑑𝑑𝑑𝑑𝑜𝑜
𝑡𝑡0
𝛷𝛷𝑜𝑜
𝑡𝑡
−𝐼𝐼
•
    
−𝜏𝜏𝑀𝑀𝐴𝐴𝑡𝑡
−𝜏𝜏𝑀𝑀𝐴𝐴ℎ
𝑡𝑡0
−𝜏𝜏𝛤𝛤𝑜𝑜
𝑡𝑡0
−𝜏𝜏𝑊𝑊−1 ⎦⎥
⎥
⎥
⎥
⎤ < 0       (4.15)               
3 Set 𝑊𝑊 = 𝜀𝜀𝑀𝑀−1, then 𝑊𝑊−1 = 𝜀𝜀−1𝑀𝑀 and the LMI can be written as follows: 
 
𝛯𝛯𝑠𝑠3 =
⎣
⎢
⎢
⎢
⎢
⎡𝑀𝑀𝛯𝛯𝑠𝑠11𝑀𝑀
•
•
•
•
•
    
𝑀𝑀𝛯𝛯𝑠𝑠12𝑀𝑀
𝑀𝑀𝛯𝛯𝑠𝑠22𝑀𝑀
•
•
•
•
    
𝜏𝜏𝑀𝑀𝜏𝜏𝑀𝑀
−𝜏𝜏𝑀𝑀𝜏𝜏𝑀𝑀
−𝜏𝜏𝜀𝜀𝑀𝑀
•
•
•
     
𝑀𝑀𝛤𝛤𝑜𝑜00
−𝛾𝛾2𝐼𝐼
•
•
    
𝑀𝑀𝑑𝑑𝑜𝑜
𝑡𝑡
𝑀𝑀𝑑𝑑𝑑𝑑𝑜𝑜
𝑡𝑡0
𝛷𝛷𝑜𝑜
𝑡𝑡
−𝐼𝐼
•
    
−𝜏𝜏𝑀𝑀𝐴𝐴𝑡𝑡
−𝜏𝜏𝑀𝑀𝐴𝐴ℎ
𝑡𝑡0
−𝜏𝜏𝛤𝛤𝑜𝑜
𝑡𝑡0
−𝜏𝜏𝜀𝜀−1𝑀𝑀⎦⎥
⎥
⎥
⎥
⎤ < 0                 (4.16)                  
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Now, we need to simplify the LMI and make all its terms linear , we do the following: 
𝛯𝛯𝑠𝑠311 = 𝑀𝑀𝛯𝛯𝑠𝑠11𝑀𝑀 = 𝑀𝑀�𝑃𝑃𝐴𝐴𝑠𝑠 + 𝐴𝐴𝑠𝑠𝑡𝑡𝑃𝑃𝑡𝑡 + 𝜏𝜏𝑠𝑠 + 𝜏𝜏𝑠𝑠𝑡𝑡 + 𝑄𝑄�𝑀𝑀 
= 𝐴𝐴𝑠𝑠𝑀𝑀 + 𝑀𝑀𝐴𝐴𝑠𝑠𝑡𝑡 + 𝑀𝑀𝜏𝜏𝑠𝑠𝑀𝑀 + 𝑀𝑀𝜏𝜏𝑠𝑠𝑡𝑡𝑀𝑀 + 𝑀𝑀𝑄𝑄𝑀𝑀 
𝛯𝛯𝑠𝑠312 = 𝑀𝑀𝛯𝛯𝑠𝑠12𝑀𝑀 = 𝑀𝑀[𝑃𝑃𝐴𝐴𝑑𝑑𝑜𝑜 − 𝜏𝜏 + 𝜏𝜏𝑡𝑡]𝑀𝑀 = 𝐴𝐴𝑑𝑑𝑜𝑜𝑀𝑀 −𝑀𝑀𝜏𝜏𝑠𝑠𝑀𝑀 + 𝑀𝑀𝜏𝜏𝑠𝑠𝑡𝑡𝑀𝑀 
𝛯𝛯𝑠𝑠313 = 𝑀𝑀𝛯𝛯𝑠𝑠22𝑀𝑀 = 𝑀𝑀�−𝜏𝜏𝑠𝑠 − 𝜏𝜏𝑠𝑠𝑡𝑡 − 𝑄𝑄�𝑀𝑀 = −𝑀𝑀𝜏𝜏𝑠𝑠𝑀𝑀 −𝑀𝑀𝜏𝜏𝑠𝑠𝑡𝑡𝑀𝑀 − 𝑀𝑀𝑄𝑄𝑀𝑀 
However, 
 𝐴𝐴𝑠𝑠 = 𝐴𝐴 + 𝐵𝐵𝐾𝐾  and 𝑑𝑑𝑠𝑠  =  𝑑𝑑𝑜𝑜  +  𝐷𝐷𝐾𝐾 
Let 𝐵𝐵 = 𝐾𝐾𝑀𝑀  
Then 𝐴𝐴𝑠𝑠𝑀𝑀 = 𝐴𝐴𝑀𝑀 + 𝐵𝐵𝐾𝐾𝑀𝑀 = 𝐴𝐴𝑀𝑀 + 𝐵𝐵𝐵𝐵 
𝑑𝑑𝑠𝑠𝑀𝑀 = 𝑑𝑑𝑜𝑜𝑀𝑀 +  𝐷𝐷𝐾𝐾𝑀𝑀 = 𝑑𝑑𝑜𝑜𝑀𝑀 +  𝐷𝐷𝐵𝐵 
However D= 0, So,  𝑑𝑑𝑠𝑠 = 𝑑𝑑𝑜𝑜  
Let 
𝜏𝜏1 = 𝑀𝑀𝜏𝜏𝑠𝑠𝑀𝑀 
𝑄𝑄1 = 𝑀𝑀𝑄𝑄𝑀𝑀 
𝜏𝜏1 = 𝑀𝑀𝜏𝜏𝑠𝑠𝑀𝑀  
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By using the performance Measure J , the LMI (4.14) is obtained. 
4.4. Extension to Two Time Delay System 
 
?̇?𝑥(𝑡𝑡) = 𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ1𝑥𝑥(𝑡𝑡 − 𝜏𝜏1) + 𝐴𝐴ℎ1𝑥𝑥(𝑡𝑡 − 𝜏𝜏2) + 𝐵𝐵𝑢𝑢(𝑡𝑡) +𝛤𝛤𝑜𝑜𝑤𝑤(𝑡𝑡)         (4.17)                                  
𝑦𝑦(𝑡𝑡) = 𝐶𝐶𝑥𝑥(𝑡𝑡) + 𝐷𝐷𝑢𝑢(𝑡𝑡) + 𝜓𝜓𝑜𝑜𝑤𝑤(𝑡𝑡) 
𝑧𝑧(𝑡𝑡) = 𝑑𝑑𝑜𝑜𝑥𝑥(𝑡𝑡) + 𝑑𝑑𝑑𝑑𝑜𝑜1𝑥𝑥(𝑡𝑡 − 𝜏𝜏1) + 𝑑𝑑𝑑𝑑𝑜𝑜2𝑥𝑥(𝑡𝑡 − 𝜏𝜏2) + 𝐷𝐷𝑜𝑜𝑢𝑢(𝑡𝑡) + 𝛷𝛷𝑜𝑜𝑤𝑤(𝑡𝑡)  
The above plant will be stable if for 0 < 𝑃𝑃 = 𝑃𝑃𝑡𝑡 , 0 < 𝑊𝑊1 = 𝑊𝑊1𝑡𝑡 , 0 < 𝑊𝑊2 = 𝑊𝑊2𝑡𝑡 ,0 <
𝑄𝑄1 = 𝑄𝑄1𝑡𝑡 , 0 < 𝑄𝑄2 = 𝑄𝑄2𝑡𝑡 ,𝜏𝜏1 ∈ ℜ𝑛𝑛×𝑛𝑛 , 𝜏𝜏2 ∈ ℜ𝑛𝑛×𝑛𝑛  and 𝜏𝜏1 ∈ ℜ𝑛𝑛×𝑛𝑛   , 𝜏𝜏2 ∈ ℜ𝑛𝑛×𝑛𝑛   the 
following LMI is satisfied: 
⎣
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎡𝛯𝛯111 𝛯𝛯121 𝛯𝛯122 𝜏𝜏1𝜏𝜏1 𝜏𝜏2𝜏𝜏2 𝑃𝑃𝛤𝛤𝑜𝑜 𝑑𝑑0𝑡𝑡 −𝜏𝜏1𝐴𝐴𝑡𝑡𝑊𝑊1 −𝜏𝜏2𝐴𝐴𝑡𝑡𝑊𝑊2
• 𝛯𝛯222 0 −𝜏𝜏1𝜏𝜏1 0 0 𝑑𝑑𝑑𝑑𝑜𝑜1𝑡𝑡 −𝜏𝜏1𝐴𝐴ℎ1𝑡𝑡𝑊𝑊1 −𝜏𝜏2𝐴𝐴ℎ1𝑡𝑡𝑊𝑊2
• • 𝛯𝛯333 0 −𝜏𝜏2𝜏𝜏2 0 𝑑𝑑𝑑𝑑𝑜𝑜2𝑡𝑡 −𝜏𝜏1𝐴𝐴ℎ2𝑡𝑡𝑊𝑊1 −𝜏𝜏2𝐴𝐴ℎ2𝑡𝑡𝑊𝑊2
• • • −𝜏𝜏1𝑊𝑊1 0 0 0 0 0
• • • • −𝜏𝜏2𝑊𝑊2 0 0 0 0
• • • • • −𝛾𝛾2𝐼𝐼 𝛷𝛷𝑜𝑜𝑡𝑡 −𝜏𝜏1𝛤𝛤𝑜𝑜𝑡𝑡𝑊𝑊1 −𝜏𝜏2𝛤𝛤𝑜𝑜𝑡𝑡𝑊𝑊2
• • • • • • −𝐼𝐼 0 0
• • • • • • • −𝜏𝜏1𝑊𝑊1 0
• • • • • • • • −𝜏𝜏2𝑊𝑊2 ⎦⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎤
< 0   
(4.18) 
where: 
𝛯𝛯111 = 𝑃𝑃𝐴𝐴 + 𝐴𝐴𝑡𝑡𝑃𝑃 + 𝜏𝜏1 + 𝜏𝜏1𝑡𝑡 + 𝜏𝜏2 + 𝜏𝜏2𝑡𝑡 + 𝑄𝑄1 + 𝑄𝑄2 
𝛯𝛯121 = 𝑃𝑃𝐴𝐴ℎ1 −𝜏𝜏1 + 𝜏𝜏1𝑡𝑡  
𝛯𝛯122 = 𝑃𝑃𝐴𝐴ℎ2 −𝜏𝜏2 + 𝜏𝜏2𝑡𝑡   
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𝛯𝛯222 = −𝜏𝜏1 − 𝜏𝜏1𝑡𝑡 − 𝑄𝑄1 
𝛯𝛯333 = −𝜏𝜏2 − 𝜏𝜏2𝑡𝑡 − 𝑄𝑄2  
Proof: 
Consider the following Lyapunov-Krasovskii functions: 
𝑉𝑉2(𝑡𝑡) = 𝑉𝑉𝑜𝑜2(𝑡𝑡) + 𝑉𝑉𝑎𝑎2(𝑡𝑡) + 𝑉𝑉𝑚𝑚2(𝑡𝑡) 
𝑉𝑉𝑜𝑜2(𝑡𝑡) = 𝑥𝑥𝑡𝑡(𝑡𝑡)𝛲𝛲𝑥𝑥(𝑡𝑡)                
𝑉𝑉𝑎𝑎2(𝑡𝑡) = ∫ ∫ ?̇?𝑥𝑡𝑡(𝛼𝛼)𝑊𝑊1?̇?𝑥𝑡𝑡𝑡𝑡+𝑠𝑠0−𝜏𝜏1 (𝛼𝛼)𝑑𝑑𝛼𝛼𝑑𝑑𝑠𝑠 + ∫ ∫ ?̇?𝑥𝑡𝑡(𝛼𝛼)𝑊𝑊2?̇?𝑥𝑡𝑡𝑡𝑡+𝑠𝑠0−𝜏𝜏2 (𝛼𝛼)𝑑𝑑𝛼𝛼𝑑𝑑𝑠𝑠                           
(4.19) 
𝑉𝑉𝑚𝑚2(𝑡𝑡) = ∫ 𝑥𝑥𝑡𝑡(𝑠𝑠)𝑄𝑄1𝑥𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡+𝜏𝜏1 𝑑𝑑𝑠𝑠 + ∫ 𝑥𝑥𝑡𝑡(𝑠𝑠)𝑄𝑄2𝑥𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡+𝜏𝜏2 𝑑𝑑𝑠𝑠                                                      
(4.20) 
= ∫ 𝑥𝑥𝑡𝑡(𝑠𝑠)𝑄𝑄1𝑥𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏1 𝑑𝑑𝑠𝑠 + ∫ 𝑥𝑥𝑡𝑡(𝑠𝑠)𝑄𝑄2𝑥𝑥(𝑠𝑠)𝑡𝑡𝑡𝑡−𝜏𝜏2 𝑑𝑑𝑠𝑠                                                                   
(4.21) 
Following the procedure done in the previous sections, we can extend the LMI for two 
time delay, as follows: 
𝑉𝑉𝑜𝑜2(𝑡𝑡) = 1𝜏𝜏1∫  �𝑥𝑥𝑡𝑡(𝑡𝑡)𝑃𝑃𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡)𝐴𝐴𝑡𝑡𝑃𝑃𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡)𝜏𝜏1𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡)𝜏𝜏1𝑡𝑡𝑥𝑥(𝑡𝑡) +𝑡𝑡𝑡𝑡−𝜏𝜏12𝑥𝑥𝑡𝑡(𝑡𝑡)�𝑃𝑃𝐴𝐴𝑑𝑑𝑜𝑜1 −𝜏𝜏1 + 𝜏𝜏1𝑡𝑡� 𝑥𝑥(𝑡𝑡 − 𝜏𝜏1) + 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏1)(−𝜏𝜏1)𝑥𝑥(𝑡𝑡 − 𝜏𝜏1) − 2𝑥𝑥𝑡𝑡(𝑡𝑡)𝜏𝜏1𝜏𝜏1?̇?𝑥(𝑠𝑠) −2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏1)  𝜏𝜏1 𝜏𝜏1?̇?𝑥(𝑠𝑠)� 𝑑𝑑𝑠𝑠 + 
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1
𝜏𝜏2  ∫  �𝑥𝑥𝑡𝑡(𝑡𝑡)𝑃𝑃𝐴𝐴 𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡) 𝐴𝐴𝑡𝑡𝑃𝑃 𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡) 𝜏𝜏2 𝑥𝑥(𝑡𝑡) + 𝑥𝑥𝑡𝑡(𝑡𝑡) 𝜏𝜏2𝑡𝑡𝑥𝑥(𝑡𝑡) +𝑡𝑡𝑡𝑡−𝜏𝜏22𝑥𝑥𝑡𝑡(𝑡𝑡)�𝑃𝑃𝐴𝐴𝑑𝑑𝑜𝑜2 −𝜏𝜏1 + 𝜏𝜏2𝑡𝑡� 𝑥𝑥(𝑡𝑡 − 𝜏𝜏2) + 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏2)(−𝜏𝜏2) 𝑥𝑥(𝑡𝑡 − 𝜏𝜏2) −2𝑥𝑥𝑡𝑡(𝑡𝑡) 𝜏𝜏2 𝜏𝜏2 ?̇?𝑥(𝑠𝑠) − 2𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏2) 𝜏𝜏2 𝜏𝜏2 ?̇?𝑥(𝑠𝑠)� 𝑑𝑑𝑠𝑠                                    (4.22) 
𝑉𝑉𝑎𝑎2(𝑡𝑡) = ∫ [(?̇?𝑥𝑡𝑡(𝑡𝑡)𝑊𝑊1?̇?𝑥(𝑡𝑡)) − (?̇?𝑥𝑡𝑡(𝑠𝑠)𝑊𝑊1?̇?𝑥(𝑠𝑠))]𝑡𝑡𝑡𝑡−𝜏𝜏1 𝑑𝑑𝑠𝑠 + ∫ [(?̇?𝑥𝑡𝑡(𝑡𝑡)𝑊𝑊2?̇?𝑥(𝑡𝑡)) −𝑡𝑡𝑡𝑡−𝜏𝜏2(?̇?𝑥𝑡𝑡(𝑠𝑠)𝑊𝑊2?̇?𝑥(𝑠𝑠))]𝑑𝑑𝑠𝑠  (4.23) 
𝑉𝑉𝑚𝑚2̇ (𝑡𝑡) =1
𝜏𝜏1  ∫  [𝑥𝑥𝑡𝑡(𝑡𝑡)𝑄𝑄1𝑥𝑥(𝑡𝑡) − 𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏1)𝑄𝑄1𝑥𝑥(𝑡𝑡 − 𝜏𝜏1)]𝑡𝑡𝑡𝑡−𝜏𝜏1 𝑑𝑑𝑠𝑠 + 1𝜏𝜏2  ∫  [𝑥𝑥𝑡𝑡(𝑡𝑡)𝑄𝑄2𝑥𝑥(𝑡𝑡) −𝑡𝑡𝑡𝑡−𝜏𝜏2
𝑥𝑥𝑡𝑡(𝑡𝑡 − 𝜏𝜏2) 𝑄𝑄2 𝑥𝑥(𝑡𝑡 − 𝜏𝜏2)]  𝑑𝑑𝑠𝑠                                                                      (4.24) 
since 
?̇?𝑥(𝑡𝑡)  = 𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ1𝑥𝑥(𝑡𝑡 − 𝜏𝜏1) + 𝐴𝐴ℎ2𝑥𝑥(𝑡𝑡 − 𝜏𝜏2)  
Next we use the term𝑠𝑠  (?̇?𝑥𝑡𝑡(𝑡𝑡)𝑊𝑊1?̇?𝑥(𝑡𝑡)) − (?̇?𝑥𝑡𝑡(𝑠𝑠)𝑊𝑊1?̇?𝑥(𝑠𝑠))   
Algebraic manipulation yields: 
?̇?𝑥𝑡𝑡(𝑡𝑡)[𝜏𝜏1𝑊𝑊1 + 𝜏𝜏2𝑊𝑊2]?̇?𝑥(𝑡𝑡) = 𝜒𝜒𝑡𝑡?̅?𝐴𝑡𝑡[𝜏𝜏1𝑊𝑊1 + 𝜏𝜏2𝑊𝑊2]?̅?𝐴𝜒𝜒 
= [𝐴𝐴     𝐴𝐴ℎ1  𝐴𝐴ℎ2   0 ]
⎣
⎢
⎢
⎡
𝑥𝑥(𝑡𝑡)
𝑥𝑥(𝑡𝑡 − 𝜏𝜏1)
𝑥𝑥(𝑡𝑡 − 𝜏𝜏2)
?̇?𝑥(𝑠𝑠) ⎦⎥⎥
⎤
  
= ?̅?𝐴𝜒𝜒(𝑡𝑡, 𝑠𝑠) ≜ ?̅?𝐴𝜒𝜒 
Therefore: 
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?̇?𝑉(𝑡𝑡) = 𝜒𝜒𝑡𝑡𝛯𝛯ℎ𝜒𝜒 + 𝜒𝜒𝑡𝑡?̅?𝐴𝑡𝑡[𝜏𝜏1𝑊𝑊1 + 𝜏𝜏2𝑊𝑊2]?̅?𝐴𝜒𝜒 
= 𝜒𝜒𝑡𝑡[𝛯𝛯ℎ + 𝜏𝜏?̅?𝐴𝑡𝑡[𝜏𝜏1𝑊𝑊1 + 𝜏𝜏2𝑊𝑊2]?̅?𝐴]𝜒𝜒                                                                (4.25) 
By using the Schur complement and the same performance measure we will obtain with 
the LMI (4.18)  
4.5. State Feedback for Two time delay Case 
 
The plant with two time delays (4.17) is stable if for 0 < 𝑃𝑃 = 𝑃𝑃𝑡𝑡 , ,0 < 𝑄𝑄11 = 𝑄𝑄11 𝑡𝑡 , 0 <
𝑄𝑄21 = 𝑄𝑄21 𝑡𝑡 ,𝜏𝜏11 ∈ ℜ𝑛𝑛×𝑛𝑛 , 𝜏𝜏21 ∈ ℜ𝑛𝑛×𝑛𝑛  and 𝜏𝜏11 ∈ ℜ𝑛𝑛×𝑛𝑛   , 𝜏𝜏21 ∈ ℜ𝑛𝑛×𝑛𝑛   the following LMI 
is satisfied: 
⎣
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎡𝛯𝛯11𝑎𝑎 𝛯𝛯121𝑎𝑎 𝛯𝛯122𝑎𝑎 𝜏𝜏1𝜏𝜏11 𝜏𝜏2𝜏𝜏12 𝑀𝑀𝛤𝛤𝑜𝑜 𝑀𝑀𝑑𝑑0 𝑡𝑡 −𝜏𝜏1𝑀𝑀𝐴𝐴𝑡𝑡 −𝜏𝜏2𝑀𝑀𝐴𝐴𝑡𝑡
• 𝛯𝛯221𝑎𝑎 0 −𝜏𝜏1𝜏𝜏11 0 0 𝑀𝑀𝑑𝑑𝑑𝑑𝑜𝑜1𝑡𝑡 −𝜏𝜏1𝑀𝑀𝐴𝐴ℎ1𝑡𝑡 −𝜏𝜏2𝑀𝑀𝐴𝐴ℎ1𝑡𝑡
• • 𝛯𝛯332𝑎𝑎 0 −𝜏𝜏2𝜏𝜏21 0 𝑀𝑀𝑑𝑑𝑑𝑑𝑜𝑜2𝑡𝑡 −𝜏𝜏1𝑀𝑀𝐴𝐴ℎ2𝑡𝑡 −𝜏𝜏2𝑀𝑀𝐴𝐴ℎ2𝑡𝑡
• • • −𝜏𝜏1𝜀𝜀1−1𝑀𝑀 0 0 0 0 0
• • • • −𝜏𝜏2𝜀𝜀2−1𝑀𝑀 0 0 0 0
• • • • • −𝛾𝛾2𝐼𝐼 𝛷𝛷�𝑜𝑜𝑡𝑡 −𝜏𝜏1𝛤𝛤�𝑜𝑜 𝑡𝑡 −𝜏𝜏2𝛤𝛤0𝑡𝑡
• • • • • • −𝐼𝐼 0 0
• • • • • • • −𝜏𝜏1𝜀𝜀1−1𝑀𝑀 0
• • • • • • • • −𝜏𝜏2𝜀𝜀2−1𝑀𝑀⎦⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎤
<
0             (4.26) 
where: 
𝛯𝛯11𝑎𝑎 = 𝐴𝐴𝑠𝑠𝑀𝑀 + 𝑀𝑀𝐴𝐴𝑠𝑠𝑡𝑡 + 𝜏𝜏11 + 𝜏𝜏11 𝑡𝑡 + 𝜏𝜏21 + 𝜏𝜏21 𝑡𝑡 + 𝑄𝑄11 + 𝑄𝑄21   = 𝐴𝐴𝑀𝑀 + 𝐵𝐵𝐵𝐵 + 𝑀𝑀𝐴𝐴𝑡𝑡 + 𝐵𝐵𝑡𝑡𝐵𝐵𝑡𝑡 + 𝜏𝜏11 + 𝜏𝜏11 𝑡𝑡 + 𝜏𝜏21 + 𝜏𝜏21𝑡𝑡 + 𝑄𝑄11 + 𝑄𝑄21   
𝑑𝑑 = 𝐾𝐾𝑀𝑀  
𝛯𝛯121𝑎𝑎 = 𝐴𝐴𝑑𝑑𝑜𝑜1𝑀𝑀 −𝜏𝜏11 + 𝜏𝜏11 𝑡𝑡  
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𝛯𝛯122𝑎𝑎 = 𝐴𝐴𝑑𝑑𝑜𝑜2𝑀𝑀 −𝜏𝜏11 + 𝜏𝜏21 𝑡𝑡   
𝛯𝛯𝑠𝑠322 = −𝜏𝜏11 − 𝜏𝜏11 𝑡𝑡 − 𝑄𝑄11  
𝛯𝛯𝑠𝑠322 = −𝜏𝜏21 − 𝜏𝜏21 𝑡𝑡 − 𝑄𝑄21  
To prove this LMI, we apply the same procedure as for one time delay to LMI 
(4.26). 
4.6. Tracking: 
 
In the previous sections, we develop the LMI by using it to stabilize the plant. However, 
we need also, in addition to stabilizing the plant, to control its behavior in the transient 
zone, so that it can follow the desired behavior. This is done by choosing a model which 
has the desired characteristics which the plant should track by forcing the error between 
model and plant to be minimum. The LMI technique is used to do that because we can 
augment the plant and the model in one LMI and we can do the stabilizing and the 
tracking also in the same LMI.  
So, if we consider the plant and model as follows: 
?̇?𝑥(𝑡𝑡) = 𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ𝑥𝑥(𝑡𝑡 − 𝜏𝜏) + 𝐵𝐵𝑢𝑢(𝑡𝑡) +𝛤𝛤𝑜𝑜𝑤𝑤(𝑡𝑡)                                              (4.27) 
?̇?𝑥𝑚𝑚 (𝑡𝑡) = 𝐴𝐴𝑚𝑚𝑥𝑥𝑚𝑚 (𝑡𝑡) + 𝐴𝐴ℎ𝑚𝑚𝑥𝑥𝑚𝑚(𝑡𝑡 − 𝜏𝜏)  
where 𝑢𝑢(𝑡𝑡) = 𝐾𝐾𝑒𝑒(𝑡𝑡) = 𝐾𝐾(𝑥𝑥𝑚𝑚 (𝑡𝑡) −  𝑥𝑥(𝑡𝑡))                                                  (4.28)                                     
?̇?𝑒(𝑡𝑡) = 𝐴𝐴𝑚𝑚�𝑥𝑥𝑚𝑚 (𝑡𝑡) −  𝑥𝑥(𝑡𝑡)� + (𝐴𝐴𝑚𝑚 − 𝐴𝐴)𝑥𝑥(𝑡𝑡) − 𝐵𝐵𝐾𝐾𝑒𝑒(𝑡𝑡) + 𝐴𝐴ℎ𝑚𝑚�𝑥𝑥𝑚𝑚 (𝑡𝑡 − 𝜏𝜏) −  𝑥𝑥(𝑡𝑡 − 𝜏𝜏)�  
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+(𝐴𝐴ℎ𝑚𝑚 − 𝐴𝐴ℎ)𝑥𝑥(𝑡𝑡 − 𝜏𝜏)  
?̇?𝑒(𝑡𝑡) = (𝐴𝐴𝑚𝑚 − 𝐵𝐵𝐾𝐾)𝑒𝑒(𝑡𝑡) + (𝐴𝐴𝑚𝑚 − 𝐴𝐴)𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ𝑚𝑚𝑒𝑒(𝑡𝑡 − 𝜏𝜏) +(𝐴𝐴ℎ𝑚𝑚 − 𝐴𝐴ℎ)𝑥𝑥(𝑡𝑡 − 𝜏𝜏) 
?̇?𝑥(𝑡𝑡) = 𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ𝑥𝑥(𝑡𝑡 − 𝜏𝜏) + 𝐵𝐵𝐾𝐾𝑒𝑒(𝑡𝑡)                                                       (4.29) 
𝑋𝑋� = �𝑥𝑥(𝑡𝑡)
𝑒𝑒(𝑡𝑡)�̇ = � 𝐴𝐴 𝐵𝐵𝐾𝐾𝐴𝐴𝑚𝑚 − 𝐴𝐴 𝐴𝐴𝑚𝑚 − 𝐵𝐵𝐾𝐾� �𝑥𝑥(𝑡𝑡)𝑒𝑒(𝑡𝑡)� + � 𝐴𝐴ℎ 0𝐴𝐴ℎ𝑚𝑚 − 𝐴𝐴ℎ 𝐴𝐴ℎ𝑚𝑚� �𝑥𝑥(𝑡𝑡 − 𝜏𝜏)𝑒𝑒(𝑡𝑡 − 𝜏𝜏)� + 𝛤𝛤𝑜𝑜𝑤𝑤(𝑡𝑡)  
(4.30) 
?̇?𝑋�(𝑡𝑡) = ?̂?𝐴𝑋𝑋� (𝑡𝑡) + ?̂?𝐴ℎ𝑋𝑋� (𝑡𝑡 − 𝜏𝜏) + 𝛤𝛤𝑜𝑜𝑤𝑤(𝑡𝑡)  
So, the plant will track the model if  0 < 𝑃𝑃� = 𝑃𝑃�𝑡𝑡 , 0 < 𝑄𝑄� = 𝑄𝑄�𝑡𝑡 , 0 <  𝑊𝑊� = 𝑊𝑊� 𝑡𝑡   & 𝜏𝜏� ∈
ℜ𝑛𝑛×𝑛𝑛  ,𝜏𝜏�  ∈ ℜ𝑛𝑛×𝑛𝑛   . The new LMI is satisfied: 
𝛯𝛯 =
⎣
⎢
⎢
⎢
⎢
⎢
⎡𝛯𝛯11
•
•
•
•
•
    
𝛯𝛯12
𝛯𝛯22
•
•
•
•
     
𝜏𝜏𝜏𝜏�
−𝜏𝜏𝜏𝜏�
−𝜏𝜏𝑊𝑊�
•
•
•
  
𝑃𝑃�𝛤𝛤𝑜𝑜00
−𝛾𝛾2𝐼𝐼
•
•
    
𝑑𝑑�𝑜𝑜
𝑡𝑡
𝑑𝑑�𝑑𝑑𝑜𝑜
𝑡𝑡0
𝛷𝛷𝑜𝑜
𝑡𝑡
−𝐼𝐼
•
    
−𝜏𝜏?̂?𝐴𝑡𝑡𝑊𝑊�
−𝜏𝜏?̂?𝐴ℎ
𝑡𝑡
𝑊𝑊�0
−𝜏𝜏𝛤𝛤𝑜𝑜
𝑡𝑡𝑊𝑊�0
−𝜏𝜏𝑊𝑊� ⎦
⎥
⎥
⎥
⎥
⎥
⎤ < 0                                                 
(4.31) 
where  
𝛯𝛯11 = 𝑃𝑃�?̂?𝐴 + ?̂?𝐴𝑡𝑡𝑃𝑃� + 𝜏𝜏� + 𝜏𝜏�𝑡𝑡 + 𝑄𝑄� 
𝛯𝛯12 = 𝑃𝑃�?̂?𝐴ℎ − 𝜏𝜏� + 𝜏𝜏�𝑡𝑡  
𝛯𝛯22 = −𝜏𝜏� − 𝜏𝜏�𝑡𝑡 − 𝑄𝑄� 
𝑑𝑑�𝑜𝑜 = [𝑑𝑑𝑜𝑜     0]𝑡𝑡  
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𝑑𝑑�𝑑𝑑𝑜𝑜 = [𝑑𝑑𝑑𝑑𝑜𝑜     0]𝑡𝑡 
Proof: 
Using the same stability analysis as before  
?̇?𝑉2𝑟𝑟 (𝑡𝑡) = 𝑉𝑉𝑜𝑜2𝑟𝑟̇ (𝑡𝑡) + 𝑉𝑉𝑎𝑎2𝑟𝑟̇ (𝑡𝑡) + 𝑉𝑉𝑚𝑚2𝑟𝑟̇ (𝑡𝑡)                                                       (4.32) 
where : 
𝑉𝑉𝑜𝑜2𝑟𝑟 (𝑡𝑡) = 𝑋𝑋�𝑡𝑡  (𝑡𝑡)𝛲𝛲�𝑋𝑋� (𝑡𝑡)                                                                                               (4.33) 
𝑉𝑉𝑎𝑎2𝑟𝑟 (𝑡𝑡) = ∫ ∫ ?̇?𝑋�𝑡𝑡(𝛼𝛼)𝑊𝑊� ?̇?𝑋�(𝛼𝛼)𝑡𝑡𝑡𝑡+𝑠𝑠0−𝜏𝜏 𝑑𝑑𝛼𝛼𝑑𝑑𝑠𝑠                                                                        (4.34)  
𝑉𝑉𝑚𝑚2𝑟𝑟 (𝑡𝑡) = ∫ 𝑋𝑋�𝑡𝑡  (𝑡𝑡)𝑄𝑄�𝑋𝑋� (𝑡𝑡)𝑡𝑡𝑡𝑡+𝜏𝜏(𝑡𝑡) 𝑑𝑑𝑠𝑠 = ∫ 𝑋𝑋�𝑡𝑡  (𝑡𝑡)𝑄𝑄�𝑋𝑋� (𝑡𝑡)𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠                                        (4.35)  
𝑉𝑉𝑜𝑜2𝑟𝑟̇ (𝑡𝑡) = ?̇?𝑋�𝑡𝑡(𝑡𝑡)𝛲𝛲�𝑋𝑋� (𝑡𝑡) + 𝑋𝑋�𝑡𝑡  (𝑡𝑡)𝛲𝛲�?̇?𝑋�(𝑡𝑡) = 2𝑋𝑋�𝑡𝑡  (𝑡𝑡)𝛲𝛲�?̇?𝑋�(𝑡𝑡) 
 = 2𝑋𝑋� (𝑡𝑡)𝛲𝛲��?̂?𝐴𝑋𝑋� (𝑡𝑡) + ?̂?𝐴ℎ1𝑋𝑋� (𝑡𝑡 − 𝜏𝜏1) + 𝛤𝛤𝑜𝑜𝑤𝑤(𝑡𝑡)�                                                (4.36) 
𝑉𝑉𝑎𝑎2𝑟𝑟̇ (𝑡𝑡) = ∫ [?̇?𝑋�𝑡𝑡(𝑡𝑡)𝑊𝑊� ?̇?𝑋�(𝑡𝑡) − ?̇?𝑋�𝑡𝑡(𝑡𝑡 + 𝑠𝑠)𝑊𝑊� ?̇?𝑋�(𝑡𝑡 + 𝑠𝑠)]0−𝜏𝜏 𝑑𝑑𝑠𝑠                                           
𝑉𝑉𝑎𝑎2𝑟𝑟̇ (𝑡𝑡) = ∫ [?̇?𝑋�𝑡𝑡(𝑡𝑡)𝑊𝑊� ?̇?𝑋�(𝑡𝑡) − ?̇?𝑋�𝑡𝑡(𝑠𝑠)𝑊𝑊� ?̇?𝑋�(𝑠𝑠)]𝑡𝑡𝑡𝑡−𝜏𝜏 𝑑𝑑𝑠𝑠                                                       (4.37) 
𝑉𝑉𝑚𝑚2𝑟𝑟̇ (𝑡𝑡) = 𝑋𝑋�𝑡𝑡  (𝑡𝑡)𝑄𝑄�𝑋𝑋� (𝑡𝑡) − 𝑋𝑋�𝑡𝑡  (𝑡𝑡 − 𝜏𝜏)𝑄𝑄�𝑋𝑋� (𝑡𝑡 − 𝜏𝜏) 
= 1
𝜏𝜏
∫ �𝑋𝑋�𝑡𝑡  (𝑡𝑡)𝑄𝑄�𝑋𝑋� (𝑡𝑡) − 𝑋𝑋�𝑡𝑡  (𝑡𝑡 − 𝜏𝜏)𝑄𝑄�𝑋𝑋� (𝑡𝑡 − 𝜏𝜏)�𝑑𝑑𝑠𝑠𝑡𝑡𝑡𝑡−𝜏𝜏                                                       (4.38) 
Again, consider the NLDT System with 𝑢𝑢(. ) ≡ 0, and let 
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𝜒𝜒𝑟𝑟(𝑡𝑡, 𝑠𝑠) = �𝑋𝑋�𝑡𝑡  (𝑡𝑡)   𝑋𝑋� (𝑡𝑡 − 𝜏𝜏)  ?̇?𝑋�(𝑠𝑠)�𝑡𝑡  
𝑉𝑉2𝑟𝑟̇ (𝑡𝑡) ≤  (𝜒𝜒𝑟𝑟𝑡𝑡(𝑡𝑡, 𝑠𝑠)𝛯𝛯ℎ2𝜒𝜒𝑟𝑟(𝑡𝑡, 𝑠𝑠) + ?̇?𝑋�𝑡𝑡(𝑡𝑡)𝑊𝑊� ?̇?𝑋�(𝑡𝑡)) < 0                                           (4.39) 
where  
𝛯𝛯ℎ = �𝑃𝑃�?̂?𝐴 + ?̂?𝐴𝑡𝑡𝑃𝑃� + 𝜏𝜏� + 𝜏𝜏�𝑡𝑡 + 𝑄𝑄�•
•
      𝑃𝑃�?̂?𝐴ℎ − 𝜏𝜏� + 𝜏𝜏�𝑡𝑡−𝜏𝜏� − 𝜏𝜏�𝑡𝑡 − 𝑄𝑄�
•
      𝜏𝜏𝜏𝜏�−𝜏𝜏𝜏𝜏�
−𝜏𝜏𝑊𝑊�
      �  
Doing the same mathematical manipulation: 
𝜏𝜏?̇?𝑋�𝑡𝑡(𝑡𝑡)𝑊𝑊� ?̇?𝑋� (𝑡𝑡)= 𝜏𝜏𝜒𝜒𝑟𝑟 𝑡𝑡 ?̃?𝐴𝑡𝑡𝑊𝑊?̃?𝐴𝜒𝜒𝑟𝑟  
 
?̇?𝑋� (𝑡𝑡) = �?̂?𝐴     ?̂?𝐴ℎ     0 � � 𝑋𝑋� (𝑡𝑡)𝑋𝑋� (𝑡𝑡 − 𝜏𝜏)
?̇?𝑋�(𝑠𝑠) � 
= ?̃?𝐴𝜒𝜒𝑟𝑟(𝑡𝑡, 𝑠𝑠) ≜ ?̃?𝐴𝜒𝜒𝑟𝑟  
Therefore: 
?̇?𝑉(𝑡𝑡) = 𝜒𝜒𝑟𝑟𝑡𝑡𝛯𝛯ℎ𝜒𝜒𝑟𝑟 + 𝜏𝜏𝜒𝜒𝑟𝑟 𝑡𝑡?̃?𝐴𝑡𝑡𝑊𝑊� ?̅?𝐴𝜒𝜒𝑟𝑟  
= 𝜒𝜒𝑟𝑟𝑡𝑡�𝛯𝛯ℎ + 𝜏𝜏?̃?𝐴𝑡𝑡𝑊𝑊� ?̃?𝐴�𝜒𝜒𝑟𝑟  
= 𝜒𝜒𝑟𝑟𝑡𝑡�𝛯𝛯ℎ + 𝜏𝜏?̃?𝐴𝑡𝑡𝑊𝑊�𝑊𝑊� −1𝑊𝑊� ?̃?𝐴�𝜒𝜒𝑟𝑟  
= 𝜒𝜒𝑟𝑟𝑡𝑡�𝛯𝛯ℎ + 𝜏𝜏?̃?𝐴𝑡𝑡𝑊𝑊� 𝜏𝜏−1 𝑊𝑊� −1𝑊𝑊� ?̃?𝐴𝜏𝜏�𝜒𝜒𝑟𝑟 < 0                                                     (4.40) 
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or 
?̇?𝑉(𝑡𝑡) < 𝜒𝜒𝑟𝑟𝑡𝑡𝛯𝛯𝜒𝜒𝑟𝑟 < 0 
By using the Schur complement and the same performance measure  
𝐽𝐽 = � �𝑧𝑧𝑡𝑡(𝑠𝑠)𝑧𝑧(𝑠𝑠) − 𝛾𝛾2𝑤𝑤𝑡𝑡(𝑠𝑠)𝑤𝑤(𝑠𝑠) + ?̇?𝑉(𝑠𝑠) − ?̇?𝑉(𝑠𝑠)�𝑑𝑑𝑠𝑠∞0  
the LMI (4.31) is obtained. 
Closed Loop: 
 
Applying the same procedure as in the state feedback section, the augmented plant is 
stable and tracks the model for  0 < 𝑃𝑃� = 𝑃𝑃�𝑡𝑡 , 0 < 𝑄𝑄�1 = 𝑄𝑄�𝑡𝑡1,  0 < 𝑄𝑄�2 = 𝑄𝑄�𝑡𝑡2,   0 <  𝑊𝑊�𝑚𝑚 =
𝑊𝑊� 𝑡𝑡𝑚𝑚  ,    𝜏𝜏� ∈ ℜ𝑛𝑛×𝑛𝑛 ,𝜏𝜏�  ∈ ℜ𝑛𝑛×𝑛𝑛  
 The new LMI is satisfied: 
⎣
⎢
⎢
⎢
⎢
⎢
⎡𝛯𝛯11𝑎𝑎 𝛯𝛯121𝑎𝑎 𝜏𝜏1𝜏𝜏1 𝑀𝑀�𝛤𝛤�𝑜𝑜 𝑀𝑀�𝑑𝑑�𝑜𝑜𝑡𝑡 −𝜏𝜏1𝑀𝑀�𝐴𝐴𝑡𝑡
• 𝛯𝛯22𝑎𝑎 −𝜏𝜏1𝜏𝜏� 0 𝑀𝑀�𝑑𝑑�𝑑𝑑𝑜𝑜1𝑡𝑡 −𝜏𝜏1𝑀𝑀�𝐴𝐴ℎ1𝑡𝑡
• • −𝜏𝜏1𝑊𝑊�𝑚𝑚1 0 0 0
• • • −𝛾𝛾2𝐼𝐼 𝛷𝛷�𝑜𝑜𝑡𝑡 −𝜏𝜏1𝛤𝛤�𝑜𝑜𝑡𝑡
• • • • −𝐼𝐼 0
• • • • • −𝜏𝜏1𝑊𝑊�𝑚𝑚 ⎦⎥
⎥
⎥
⎥
⎥
⎤
< 0                                    (4.41) 
where: 
𝛯𝛯11𝑎𝑎 = 𝑀𝑀�?̂?𝐴 + ?̂?𝐴𝑡𝑡𝑀𝑀� − 𝐵𝐵�𝑑𝑑� − 𝑑𝑑�𝑡𝑡𝐵𝐵�𝑡𝑡 + 𝜏𝜏� + 𝜏𝜏�𝑡𝑡 + 𝑄𝑄�       
𝑑𝑑� = 𝐾𝐾𝑀𝑀�   
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𝛯𝛯12𝑎𝑎 = 𝛯𝛯12 = 𝑀𝑀�?̂?𝐴ℎ − 𝜏𝜏� + 𝜏𝜏�𝑡𝑡   
𝛯𝛯22𝑎𝑎 = −𝜏𝜏� − 𝜏𝜏�𝑡𝑡 − 𝑄𝑄�  
𝑑𝑑�𝑜𝑜 = [𝑑𝑑𝑜𝑜     0]𝑡𝑡  
𝑑𝑑�𝑑𝑑𝑜𝑜 = [𝑑𝑑𝑑𝑑𝑜𝑜     0]𝑡𝑡 
𝑊𝑊�𝑚𝑚 = 𝑊𝑊� −1  
4.6. Tracking Development for Two Time Delay 
 
Tracking derivation for the two time delay case can be obtained by following the same 
procedure as for one time delay. So, we consider the plant and model as follows: 
?̇?𝑥(𝑡𝑡) = 𝐴𝐴𝑥𝑥(𝑡𝑡) + 𝐴𝐴ℎ1𝑥𝑥(𝑡𝑡 − 𝜏𝜏1) + 𝐴𝐴ℎ2𝑥𝑥(𝑡𝑡 − 𝜏𝜏2) + 𝐵𝐵𝑢𝑢(𝑡𝑡) +𝛤𝛤𝑜𝑜𝑤𝑤(𝑡𝑡) 
?̇?𝑥𝑚𝑚 (𝑡𝑡) = 𝐴𝐴𝑚𝑚𝑥𝑥𝑚𝑚 (𝑡𝑡) + 𝐴𝐴ℎ𝑚𝑚1𝑥𝑥𝑚𝑚 (𝑡𝑡 − 𝜏𝜏1) + 𝐴𝐴ℎ𝑚𝑚2𝑥𝑥𝑚𝑚 (𝑡𝑡 − 𝜏𝜏2)  
where 𝑢𝑢(𝑡𝑡) = 𝐾𝐾𝑒𝑒(𝑡𝑡) = 𝐾𝐾(𝑥𝑥𝑚𝑚 (𝑡𝑡) −  𝑥𝑥(𝑡𝑡)) 
𝑋𝑋� = �𝑥𝑥(𝑡𝑡)
𝑒𝑒(𝑡𝑡)�̇ = � 𝐴𝐴 𝐵𝐵𝐾𝐾𝐴𝐴𝑚𝑚 − 𝐴𝐴 𝐴𝐴𝑚𝑚 − 𝐵𝐵𝐾𝐾� �𝑥𝑥(𝑡𝑡)𝑒𝑒(𝑡𝑡)� + � 𝐴𝐴ℎ1 0𝐴𝐴ℎ𝑚𝑚1 − 𝐴𝐴ℎ1 𝐴𝐴ℎ𝑚𝑚1� �𝑥𝑥(𝑡𝑡 − 𝜏𝜏1)𝑒𝑒(𝑡𝑡 − 𝜏𝜏1)� +
�
𝐴𝐴ℎ2 0
𝐴𝐴ℎ𝑚𝑚2 − 𝐴𝐴ℎ2 𝐴𝐴ℎ𝑚𝑚2� �𝑥𝑥(𝑡𝑡 − 𝜏𝜏2)𝑒𝑒(𝑡𝑡 − 𝜏𝜏2)� + 𝛤𝛤𝑜𝑜𝑤𝑤(𝑡𝑡)                                                              (4.42) 
?̇?𝑋�(𝑡𝑡) = ?̂?𝐴𝑋𝑋� (𝑡𝑡) + ?̂?𝐴ℎ1𝑋𝑋� (𝑡𝑡 − 𝜏𝜏1) + ?̂?𝐴ℎ2𝑋𝑋� (𝑡𝑡 − 𝜏𝜏2) + 𝛤𝛤𝑜𝑜𝑤𝑤(𝑡𝑡)  
After this analysis , we can formulate the LMI for open loop case and the closed loop as 
follows: 
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(1) Open Loop: 
the plant will track the model for  0 < 𝑃𝑃� = 𝑃𝑃�𝑡𝑡 , 0 < 𝑄𝑄�1 = 𝑄𝑄�1𝑡𝑡 , 0 < 𝑄𝑄�2 = 𝑄𝑄�2𝑡𝑡 , 0 <  𝑊𝑊�1 =
𝑊𝑊�1𝑡𝑡 , 0 <  𝑊𝑊�2 = 𝑊𝑊�2𝑡𝑡   , 𝜏𝜏�1 ∈ ℜ𝑛𝑛×𝑛𝑛 ,𝜏𝜏�2 ∈ ℜ𝑛𝑛×𝑛𝑛  ,𝜏𝜏�1  ∈ ℜ𝑛𝑛×𝑛𝑛 ,𝜏𝜏�2  ∈ ℜ𝑛𝑛×𝑛𝑛   and the new 
LMI is satisfied: 
⎣
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎡𝛯𝛯111 𝛯𝛯121 𝛯𝛯122 𝜏𝜏1𝜏𝜏�1 𝜏𝜏2𝜏𝜏�2 𝑃𝑃�𝛤𝛤�𝑜𝑜 𝑑𝑑�𝑜𝑜 𝑡𝑡 −𝜏𝜏1𝐴𝐴𝑡𝑡𝑊𝑊�1 −𝜏𝜏2𝐴𝐴𝑡𝑡𝑊𝑊�2
• 𝛯𝛯221 0 −𝜏𝜏1𝜏𝜏�1 0 0 𝑑𝑑�𝑑𝑑𝑜𝑜1𝑡𝑡 −𝜏𝜏1𝐴𝐴ℎ1𝑡𝑡𝑊𝑊�1 −𝜏𝜏2𝐴𝐴ℎ1𝑡𝑡𝑊𝑊�2
• • 𝛯𝛯332 0 −𝜏𝜏2𝜏𝜏�2 0 𝑑𝑑�𝑑𝑑𝑜𝑜2𝑡𝑡 −𝜏𝜏1𝐴𝐴ℎ2𝑡𝑡𝑊𝑊�1 −𝜏𝜏2𝐴𝐴ℎ2𝑡𝑡𝑊𝑊�2
• • • −𝜏𝜏1𝑊𝑊�1 0 0 0 0 0
• • • • −𝜏𝜏2𝑊𝑊�2 0 0 0 0
• • • • • −𝛾𝛾2𝐼𝐼 𝛷𝛷𝑜𝑜�𝑡𝑡 −𝜏𝜏1𝛤𝛤𝑜𝑜𝑡𝑡𝑊𝑊�1 −𝜏𝜏2𝛤𝛤𝑜𝑜𝑡𝑡𝑊𝑊�2
• • • • • • −𝐼𝐼 0 0
• • • • • • • −𝜏𝜏1𝑊𝑊�1 0
• • • • • • • • −𝜏𝜏2𝑊𝑊�2 ⎦⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎤
< 0   
(4.44) 
where: 
𝛯𝛯111 = 𝑃𝑃�?̂?𝐴 + ?̂?𝐴𝑡𝑡𝑃𝑃� + 𝜏𝜏�1 + 𝜏𝜏�1𝑡𝑡 + 𝜏𝜏�2 + 𝜏𝜏�2𝑡𝑡 + 𝑄𝑄�1 + 𝑄𝑄�2       
𝛯𝛯121 = 𝑃𝑃�?̂?𝐴ℎ1 − 𝜏𝜏�1 + 𝜏𝜏�1𝑡𝑡   
𝛯𝛯122 = 𝑃𝑃�?̂?𝐴ℎ2 − 𝜏𝜏�2 + 𝜏𝜏�2𝑡𝑡   
𝛯𝛯221 = −𝜏𝜏�1 − 𝜏𝜏�1𝑡𝑡 − 𝑄𝑄�1  
𝛯𝛯332 = −𝜏𝜏�2 − 𝜏𝜏�2𝑡𝑡 − 𝑄𝑄�2  
Closed Loop: 
So, the plant is stable and tracks the model for  0 < 𝑃𝑃� = 𝑃𝑃�𝑡𝑡 , 0 < 𝑄𝑄�1 = 𝑄𝑄�𝑡𝑡1,  
80 
 
 
 
0 < 𝑄𝑄�2 = 𝑄𝑄�𝑡𝑡2,   0 <  𝑊𝑊�𝑚𝑚1 = 𝑊𝑊� 𝑡𝑡𝑚𝑚1 ,0 <  𝑊𝑊�𝑚𝑚2 = 𝑊𝑊� 𝑡𝑡𝑚𝑚2,   & 𝜏𝜏�1 ∈ ℜ𝑛𝑛×𝑛𝑛 ,𝜏𝜏�2 ∈ ℜ𝑛𝑛×𝑛𝑛 ,𝜏𝜏�1  ∈
ℜ𝑛𝑛×𝑛𝑛 ,𝜏𝜏�2  ∈ ℜ𝑛𝑛×𝑛𝑛   and the new LMI is satisfied: 
⎣
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎢
⎡𝛯𝛯11𝑎𝑎 𝛯𝛯121𝑎𝑎 𝛯𝛯122𝑎𝑎 𝜏𝜏1𝜏𝜏1 𝜏𝜏2𝜏𝜏2 𝑀𝑀�𝛤𝛤�𝑜𝑜 𝑀𝑀�𝑑𝑑�𝑜𝑜𝑡𝑡 −𝜏𝜏1𝑀𝑀�𝐴𝐴𝑡𝑡 −𝜏𝜏2𝑀𝑀�𝐴𝐴𝑡𝑡
• 𝛯𝛯221𝑎𝑎 0 −𝜏𝜏1𝜏𝜏�1 0 0 𝑀𝑀�𝑑𝑑�𝑑𝑑𝑜𝑜1𝑡𝑡 −𝜏𝜏1𝑀𝑀�𝐴𝐴ℎ1𝑡𝑡 −𝜏𝜏2𝑀𝑀�𝐴𝐴ℎ1𝑡𝑡
• • 𝛯𝛯332𝑎𝑎 0 −𝜏𝜏2𝜏𝜏�2 0 𝑀𝑀�𝑑𝑑�𝑑𝑑𝑜𝑜2𝑡𝑡 −𝜏𝜏1𝑀𝑀�𝐴𝐴ℎ2𝑡𝑡 −𝜏𝜏2𝑀𝑀�𝐴𝐴ℎ2𝑡𝑡
• • • −𝜏𝜏1𝑊𝑊�𝑚𝑚1 0 0 0 0 0
• • • • −𝜏𝜏2𝑊𝑊�𝑚𝑚2 0 0 0 0
• • • • • −𝛾𝛾2𝐼𝐼 𝛷𝛷�𝑜𝑜𝑡𝑡 −𝜏𝜏1𝛤𝛤�𝑜𝑜𝑡𝑡 −𝜏𝜏2𝛤𝛤�𝑜𝑜𝑡𝑡
• • • • • • −𝐼𝐼 0 0
• • • • • • • −𝜏𝜏1𝑊𝑊�𝑚𝑚1 0
• • • • • • • • −𝜏𝜏2𝑊𝑊�𝑚𝑚1 ⎦⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎥
⎤
< 0    
(4.45) 
where: 
𝛯𝛯11 = 𝑀𝑀�?̂?𝐴 + ?̂?𝐴𝑡𝑡𝑀𝑀� − 𝐵𝐵�𝑑𝑑� − 𝑑𝑑�𝑡𝑡𝐵𝐵�𝑡𝑡 + 𝜏𝜏�1 + 𝜏𝜏�1𝑡𝑡 + 𝜏𝜏�2 + 𝜏𝜏�2𝑡𝑡 + 𝑄𝑄�1 + 𝑄𝑄�2       
𝑑𝑑� = 𝐾𝐾𝑀𝑀�   
𝛯𝛯121𝑎𝑎 = 𝑀𝑀�?̂?𝐴ℎ1 −𝜏𝜏�1 + 𝜏𝜏�1𝑡𝑡   
𝛯𝛯122𝑎𝑎 = 𝑀𝑀�?̂?𝐴ℎ2 −𝜏𝜏�2 + 𝜏𝜏�2𝑡𝑡   
𝛯𝛯221𝑎𝑎 = −𝜏𝜏�1 − 𝜏𝜏�1𝑡𝑡 − 𝑄𝑄�1  
𝛯𝛯332𝑎𝑎 = −𝜏𝜏�2 − 𝜏𝜏�2𝑡𝑡 − 𝑄𝑄�2  
𝑊𝑊�𝑚𝑚1 = 𝑊𝑊�1−1  
𝑊𝑊�𝑚𝑚2 = 𝑊𝑊�2−1  
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CHAPTER 5 
 
RESULTS & ANALYSIS 
5.1. Linear Simulation: 
 
This chapter will show the results of the derived LMI in the treatment of diabetes patients 
and it will discuss and analyze the results and their possibility to be applied in medical 
practice. In this part we will use the linearized model in simulation for testing. Six main 
issues will be discussed here to evaluate the performance of the controller. 
  
5.1.1.  Stability Analysis: 
 
1 • Open Loop Tracking.
2 • closed loop tracking (State feedback).
3 • Time Delay analysis.
4 • Model Mismatch.
5 • Meal Disturbance.
6 • Parameter Varitions.
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In this section, we will show how the plant track the model (without state feedback 
control) 
 
Figure 5.7: Glucose Response. 
 
 
Figure 5.8 : Insulin Response. 
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This figure shows the open loop response for both glucose and insulin due to initial condition. 
We can notice the effect of two time delay (the first one in insulin figure at t = 6 min and the 
second one in glucose response at t = 10 min). It is clear that the plant succees in tracking the 
dynamic of the model with minimum error.  
5.1.2.  State feedback control 
  
 
Figure 5.9: Glucose Response with state feedback control. 
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Figure 5.10: Insulin Response with state feedback control. 
 
(1) Gain = [0.1242   -10.9445    -0.1193     9.0253]. 
(2) Gama = 0.8566. 
We notice here that the controller can stabilize the plant and force it to track the dynamic 
of the model with a begging reasonable gain and rejection ratio. Also, we notice that the 
second state (insulin) increases. 
5.1.3. Time Delay Analysis: 
 
In this section we will do the analysis for two issues: 
A. We use constant uncertain bounded time delay, and the maximum time 
delays 𝜏𝜏1 = 20 min𝑎𝑎𝑛𝑛𝑑𝑑 𝜏𝜏2 = 40 𝑚𝑚𝑚𝑚𝑛𝑛. To show this assumption is valid, we will 
test the control design based on the maximum time delay. 
B. We will test time delay variations with respect to the nominal time delay on which 
the control design is based (robustness analysis).  
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Part A: 
 
 
 
Figure 5.11: Glucose Response due to Time delay change. 
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Table 5.4: Gain & Rejection Ratio Comparison for time delay change. 
Case Gain (K) Gama  (𝜸𝜸) 
𝝉𝝉𝟏𝟏 = 𝟔𝟔𝐦𝐦𝐦𝐦𝐦𝐦𝒂𝒂𝒖𝒖𝒂𝒂 𝝉𝝉𝟐𝟐 = 𝟏𝟏𝟏𝟏 𝒃𝒃𝒊𝒊𝒖𝒖 0.1038   -6.6834   -0.1022    4.8854 0.8343 
𝝉𝝉𝟏𝟏 = 𝟐𝟐𝟏𝟏𝐦𝐦𝐦𝐦𝐦𝐦𝒂𝒂𝒖𝒖𝒂𝒂 𝝉𝝉𝟐𝟐 = 𝟒𝟒𝟏𝟏 𝒃𝒃𝒊𝒊𝒖𝒖 0.4168  -14.9944    0.0267   14.4645 0.9626 
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Figure 5.12: Insulin Glucose Response due to Time delay change 
 
Table 5.5: : Accuracy Analysis due to Time delay change. 
Case  max  error mean  error 
𝝉𝝉𝟏𝟏 = 𝟔𝟔𝐦𝐦𝐦𝐦𝐦𝐦, 𝝉𝝉𝟐𝟐 = 𝟏𝟏𝟏𝟏 𝒃𝒃𝒊𝒊𝒖𝒖 G:   10.1157mg/dl 
 
G:   -0.2469mg/dl 
 
I:  8.2795µU/ml 
 
I:  1.8777 µU/ml 
 
𝝉𝝉𝟏𝟏 = 𝟐𝟐𝟏𝟏𝐦𝐦𝐦𝐦𝐦𝐦𝒂𝒂𝒖𝒖𝒂𝒂 𝝉𝝉𝟐𝟐 = 𝟒𝟒𝟏𝟏 𝒃𝒃𝒊𝒊𝒖𝒖 G:   10.1762mg/dl 
 
G:   1.7874mg/dl 
 
I:  8.2795 µU/ml 
 
I:  1.3548 µU/ml 
 
 
We notice that as time delay increases: 
1. The gain K increases. 
2. Rejection ratio 𝛾𝛾 increases. 
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3. The response will be slower and it takes more time to reach steady-state value. 
4. Comparing the error the two cases, we notice this maximum of the error is almost 
the same. This is a good point because, as the time delay increases, the controlled 
variable (Glucose) and insulin do not go beyond the physical range. 
However, the system is still able to stabilize the plant which shows that our assumption 
on type of used time delay is valid for our case. 
Part B: 
 
Figure 5.13: Glucose Response due to Time delay variations (Robustness analysis). 
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Figure 5.14: Insulin Response due to Time delay variations (Robustness analysis). 
 We can notice that, as the time delay increases, the dynamic of the system becomes slower and it 
takes more time to reach to the steady-state value, and we can notice the effect of the two time 
delays on insulin clearly as the delay becomes larger. 
5.1.4.  Model Mismatch: 
In this section, we change the dynamic speed of the model (by changing the eigenvalues by a 
certain percentage) and we see the effect on the plant. In other words, Am = ( Ap+ d*Ap). 
Table 5.6: Gain and rejection ratio rejection for model mismatch. 
Delta Gain (K) Gama 
-20 % 0.0427   -8.9424   -0.0946    4.1549 0.7813 
-40 % 0.0902   -7.7323   -0.0855    4.3060 0.8310 
0% 0.1155   -7.1069   -0.0836    4.6569 0.8337 
20 % 0.1348   -6.5382   -0.0808    5.0070 0.8345 
40 % 0.1514   -6.0301   -0.0768    5.3797 0.8349 
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(a) Glucose response: 
 
Figure 5.15: Glucose Response for various reference models selection. 
 
Figure 5.16: Glucose error for various reference models selection. 
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b) Insulin: 
 
Figure 5.17: Insulin response for various reference models selection. 
 
Figure 5.18: Insulin error for various reference models selection. 
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There, as the difference between dynamic speed of the plant and model (the magnitude of 
their eigenvalue) increase the error also increases and the controller takes more time to 
stabilize the system and to reach steady-state value. Also, as the difference becomes 
larger, the required gain and rejection ratio increases accordingly. So, the selection of the 
model affects the performance of the controller mainly in terms of transient error. 
5.1.5.  Meal Disturbance: 
 
One of the important issues which several controllers failed to overcome is the meal 
disturbance. In fact, overcoming this problem is difficult because of the following 
reasons: 
1. People usually eat several meals at different periods and with mixed content 
(carbohydrate, meat, fat, vegetables…..). 
2. These meals contain several types of glucose (simple – compound). 
3. The digestion and absorbing of these sugar types vary in terms of time and 
methodology. 
4. Patient’s situation, activity, age, health have a significant effect on the glucose 
level in the patient's blood. 
5. Some of the sugar is converted and stored as fat in the cells. 
The normal situation is for the glucose level to be in the range 70-110 mg/dl 
(normalglycemia) and the acceptable range is in the range 60-140 mg/dl. In fact, even in 
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the normal person, the glucose level can exceed this range, but the pancreas can 
overcome this situation by injecting insulin into the blood.  
 The disturbance can be positive (meal disturbance) or negative due to different reasons 
which make the glucose level drop below the desired level. 
Let us test different levels of disturbance at different periods and check the maximum 
level that the controller can sustain with the following procedure: 
Two disturbances are inserted, the former is in transient zone, and the latter is  in steady-
state zone, and each of them is of period 500 sample.  
(1) 200 mg per sample (200*500 mg = 100 g) of glucose. 
 
Figure 5.19: Glucose Response due to 100 g of meal disturbance. 
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Figure 5.20: Insulin Response due to 100 g of meal disturbance. 
 (2) 400 mg per sample (400*500 mg = 200 g) of glucose: 
 
Figure 5.21: Glucose Response due to 200 g of meal disturbance. 
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Figure 5.22: Insulin Response due to 200 g of meal disturbance. 
                    (3) 800 mg per sample (800*500 mg = 400 g) of glucose: 
 
Figure 5.23: Glucose Response due to 400 g of meal disturbance. 
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Figure 5.24: Insulin Response due to 400 g of meal disturbance. 
 (4) 1600 mg per sample (1600*500 mg = 800 g) of glucose: 
0 10 20 30 40 50 60 70 80 90 100
20
30
40
50
60
70
80
90
100
110
120
Time (min)
In
su
lin
 µ
U/
m
l
Insulin
 
 
plant
model
96 
 
 
 
 
Figure 5.25: Glucose Response due to 800 g of meal disturbance. 
 
Figure 5.26: Insulin Response due to 800 g of meal disturbance. 
 (5) 2600 mg per sample (1600*500 mg = 1300 g = 1.3 KG) of glucose: 
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Figure 5.27: Glucose Response due to 1.3 kg of meal disturbance. 
 
Figure 5.28: Insulin Response due to 1.3 k g of meal disturbance. 
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Even with large meal disturbance, the controller can stabilize the plant and keep in the 
acceptable range. Even if it exceeds this range temporarily it returns to the normal range. 
 The maximum limit for our case is 800 g = 0.8 Kg of pure glucose which rarely happens 
in real cases. 
The level of glucose increases when the disturbance enters the system because we are 
using feedback type and we cannot use feedforword techniques because the meal 
disturbance is difficult to measure. This is done by the pancreas in normal people. 
(B) Negative Disturbances: 
(1) 600 mg per sample (-600*500 mg = -300 g = 0.3 KG) of glucose: 
 
Figure 5.29: Glucose Response due to negative disturbance of 300 g. 
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Figure 5.30: Insulin Response due to negative disturbance of 300 g. 
We notice our system reacts to other cases when the glucose level drops, and the level of 
insulin drops according to the system at the certain level. 
This point is important because, as we mentioned before, the control techniques used here 
or in the other studies consider only the case of hyperglycemia (when the level of glucose 
increases). So our controller mitigates the effect of glucose's level drop by reducing the 
level of insulin in the blood. 
5.1.6. Parameter variations 
 
The parameter values of the two time delay model were identified from experimental 
data. However, these are nominal values and can vary in the same patient or from one 
patient to another because of several factors such as age, activity, weight & health of the 
patient. In this section we will see the effect of the parameter variations of the patient on 
the performance of the system.  
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We will change each parameter (the model has 18 parameters) alone to see which of them 
has a significant effect on performance when it varies.  
(1) Rm: 
 
Figure 5.31: Glucose Response due to variation of parameter Rm. 
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Figure 5.32: Insulin Response due to variation of parameter Rm. 
 (2) C1: 
 
Figure 5.33: Glucose Response due to variation of parameter C1. 
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Figure 5.34: Insulin Response due to variation of parameter C1. 
(3) Vg: 
 
Figure 5.35: Glucose Response due to variation of parameter Vg. 
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Figure 5.36: Insulin Response due to variation of parameter Vg. 
(4) a1: 
 
Figure 5.37: Glucose Response due to variation of parameter a1. 
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Figure 5.38: Insulin Response due to variation of parameter a1. 
 (6) Ub: 
 
Figure 5.39: Glucose Response due to variation of parameter Ub. 
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Figure 5.40: Insulin Response due to variation of parameter Ub. 
(7) C2: 
 
Figure 5.41: Glucose Response due to variation of parameter C2. 
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Figure 5.42: Insulin Response due to variation of parameter C2. 
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(8) C3: 
 
Figure 5.43: Glucose Response due to variation of parameter C3. 
 
Figure 5.44: Insulin Response due to variation of parameter C3. 
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(9) U0: 
 
Figure 5.45: Glucose Response due to variation of parameter U0. 
 
Figure 5.46: Insulin Response due to variation of parameter U0. 
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(10) Um 
 
Figure 5.47: Glucose Response due to variation of parameter Um. 
 
Figure 5.48: Insulin Response due to variation of parameter Um. 
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 (11) Beta: 
 
Figure 5.49: Glucose Response due to variation of parameter Beta. 
 
Figure 5.50: Insulin Response due to variation of parameter Beta. 
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(12) C4: 
 
Figure 5.51: Glucose Response due to variation of parameter C4. 
 
Figure 5.52: Insulin Response due to variation of parameter C4. 
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(13) Vi: 
 
Figure 5.53: Glucose Response due to variation of parameter Vi. 
 
Figure 5.54: Insulin Response due to variation of parameter Vi. 
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 (15) ti: 
 
Figure 5.55: Glucose Response due to variation of parameter ti. 
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Figure 5.56: Insulin Response due to variation of parameter ti. 
 (16) E: 
 
Figure 5.57: Glucose Response due to variation of parameter E. 
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Figure 5.58: Insulin Response due to variation of parameter E. 
 (17) Rg: 
 
Figure 5.59: Glucose Response due to variation of parameter Rg. 
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Figure 5.60: Insulin Response due to variation of parameter Rg. 
(18) Alpha: 
 
Figure 5.61: Glucose Response due to variation of parameter alpha. 
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Figure 5.62: Insulin Response due to variation of parameter alpha. 
 (19) Vp: 
 
Figure 5.63: Glucose Response due to variation of parameter Vp. 
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Figure 5.64: Insulin Response due to variation of parameter Vp. 
(20) C5: 
 
Figure 5.65: Glucose Response due to variation of parameter C5. 
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Figure 5.66: Insulin Response due to variation of parameter C5. 
Changing the parameter of the system by +/- 20%  does not affect the performance of the system 
for most of the model parameters. Five parameters show notable effects. These parameters are: 
C5 , C3 , Vp, Vg, Rg , Um 
Medical explanation of this variation:  
1) Rg, C5, Vp are parameters of f5
2) Um, C3 & Vg are parameters of f
 which represent the hepatic glucose production. 
Changing these parameters affects the process of converting the stored sugar and fat to 
glucose which are then sent to the blood which, in turn, affects glucose concentration in 
the blood. 
3 & f4. The nonlinear term f3* f4
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body. So, the variation of these parameters has a direct effect on the glucose 
concentration. 
For both cases, as glucose concentration varies due to parameter variations, the insulin 
concentration also varies in the same direction to compensate for these variations. 
Despite parameter variations, the system is still stable and it reaches the steady-state 
value in the normal range. 
5.2. Nonlinear Simulation Validation 
 
In the last section we tested our design by using a linearized model which showed 
interesting results .However, the real situation is represented by the nonlinear model. So, 
we need to use the nonlinear model in simulation, instead of the linearized one, to verify 
our design and to show its applicability to the treatment of diabetes patients. 
      5.2.1. State Feedback (Closed Loop) 
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Figure 5.67: Glucose Response (closed loop). 
 
Figure 5.68:  Insulin Response (State Feedback). 
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  5.2.3. Time Delay Analysis: 
         (A) Maximum Time Delay Testing: 
 
Figure 5.69: Glucose Response (max time delay). 
 
Figure 5.70: Insulin Response (max time delay). 
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        B) Time delay Variations (Robustness Analysis): 
 
Figure 5.71: Glucose Response for time delay variations. 
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Figure 5.72: Insulin Response for time delay variations.  
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5.2.3. Model Mismatch: 
 
 
Figure 5.73: Glucose Response for model mismatch. 
0 10 20 30 40 50 60 70 80 90 100
80
100
120
140
160
180
200
220
Glucose -- Model Mismatch
Time (min)
G
lu
co
se
 m
g/
dl
 
 
-40 %
-20%
0%
20%
40%
model
126 
 
 
 
 
Figure 5.74: Insulin Response for model mismatch. 
5.2.4. Disturbance Analysis: 
 
In this section we will test our design due to various glucose dosage (meals) and we will 
compare it to the linear model results. 
(a) 100 mg 
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Figure 5.75: Glucose Response with 100 mg meal disturbance. 
 
Figure 5.76: Insulin Response with 100 mg meal disturbance. 
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(b) 200 mg: 
 
Figure 5.77: Glucose Response with 200 mg meal disturbance. 
 
Figure 5.78: Insulin Response with 200 mg meal disturbance. 
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(2) 400 mg: 
 
Figure 5.79: Glucose Response with 400 mg meal disturbance. 
 
Figure 5.80: Insulin Response with 400 mg meal disturbance. 
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(e) 800 mg: 
 
Figure 5.81: Glucose Response with 800 mg meal disturbance. 
 
Figure 5.82: Insulin Response with 800 mg meal disturbance. 
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f) 1000 mg: 
 
Figure 5.83: Glucose Response with 1000 mg meal disturbance. 
 
Figure 5.84: Insulin Response with 1000 mg meal disturbance. 
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We can notice  from previous simulation that the maximum amount of meal which our design can 
handle is about  1000 mg per sample which in our case ( 1000* 500 = 500 g) while  in the linear 
case the maximum limit is 800 g. in fact, this is a good result from mdeical point of view because 
it is also  an extreme case and it is rarley happen. 
b) Negative disturbance: 
 
Figure 5.85: Glucose Response with negative meal disturbance of 200 mg. 
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Figure 5.86: Insulin Response with negative meal disturbance of 200 mg. 
5.2.5. Parameter variations: 
 
In this section, we will test the parameter which shows a significant or notable effect in linearized 
model analysis. 
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 (a) C3: 
 
Figure 5.87: Glucose Response due to variation of parameter C3. 
 
Figure 5.88: Insulin Response due to variations of parameter C3. 
 
0 10 20 30 40 50 60 70 80 90 100
80
100
120
140
160
180
200
Glucose -- Parameter Varaition (C3)
Time (min)
G
lu
co
se
 m
g/
dl
 
 
-40 %
-20%
0%
20%
40%
0 10 20 30 40 50 60 70 80 90 100
5
10
15
20
25
30
35
40
45
Insulin -- Parameter Varaition  (C3)
Time (min)
In
su
lin
 µ
U/
m
l
 
 
-40 %
-20%
0%
20%
40%
135 
 
 
 
 (b) C5: 
 
Figure 5.89: Glucose Response due to variation of parameter C5. 
 
Figure 5.90: Insulin Response due to variation of parameter C5. 
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(c) Vg: 
 
Figure 5.91: Glucose Response due to variations of parameter Vg. 
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Figure 5.92: Insulin Response due to variation of parameter Vg. 
 (d) Vp: 
 
Figure 5.93: Glucose Response due to variation of parameter Vp. 
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Figure 5.94:  Insulin Response due to variation of parameter Vp. 
 (e) Rg 
 
Figure 5.95: Glucose Response due to variation of parameter Rg. 
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Figure 5.96: Insulin Response due to variation of parameter Rg. 
 (f) Um: 
 
Figure 5.97: Glucose Response due to variation of parameter Um. 
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Figure 5.98:  Insulin Response due to variation of parameter Um. 
From previous simulations we can conclude that our design can sustain parameter 
variations.   
To sum up this section, we notice that our linear estimation for the linear simulation is 
accurate. Also, by validating our design with the nonlinear model in the simulation, we 
reveal the possibility of implementing the new controller in treating diabetic patients. 
Also, it shows the capability to deal with main variables that are varying and affecting 
glucose level in the blood and responding in accurate manner to such variations. In 
addition,   the results show that our design satisfies medical requirements which is a main 
point in assessing system performance. 
Conclusion & Future work: 
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Diabetes is one of the common diseases in the world. A lot of work is done in both 
mathematical modeling and control techniques to automate insulin delivery to the 
patients.  Some of these techniques are implemented for special cases but none of them is 
fully approved for general use. 
In this study, we used the two time model to represent the real process and LMI tools to 
drive the automated insulin delivery algorithm. We tested our work by simulating the 
linearized model and we validated it by using the nonlinear model. Also, we tested our 
design for variations in time delays and parameter variations and injection of meal 
disturbance.  The result of our design is promising and agrees with medical requirements. 
So, we think that our design can be used to treat most diabetes cases. 
Our design can handle parameter variations and model parameters which usually vary 
due to several factors. To improve this work and increase the efficiency of the controller, 
we recommend adaptive identification of model parameters. Moreover, we recommend 
cooperation between medical and control groups. This will allow for a deeper 
understanding of the real system by performing more analysis on the control design. 
Also, it will help in identifying and selecting the desired criteria such as response speed 
and maximum overshoot for each case.   
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